---
title: "Biotech convertible notes, term loans and debt financing"
url: "https://aibio.space/debt-financing/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "316 stories, updated every morning. Convertible notes, term loans, credit facilities, note sales and other debt raised by public biotech companies, newest…"
---

# Convertible notes

Convertible notes, term loans, credit facilities, note sales and other debt raised by public biotech companies, newest first. Every story names the lenders and links its primary source.

Stock offerings and other equity raises are in [Financings](https://aibio.space/financings/).

Convertible notes · 2026-10-30

## [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Horizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.

PTHS

A trading board being updated by hand. Photo: Carol M Highsmith, CC0, via rawpixel

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

The 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37.

RGEN

2026-10-30

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.

FOXO

2026-10-29

Debt Financing

### [Altimmune draws $10.0 million third tranche from Hercules loan facility](https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/)

Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.

ALT

2026-10-29

Debt Financing

### [SANUWAVE gets JPMorgan waiver on fixed charge ratio, tightens limits](https://aibio.space/news/sanuwave-gets-jpmorgan-waiver-fixed-charge-ratio-tightens-limits/)

The amendment lowers a prepayment figure and three investment baskets from $500,000 to $250,000 and requires Required Lenders consent for certain acquisitions and equity redemptions. JPMorgan Chase Bank, N.A. is administrative agent.

SNWV

2026-10-28

## More convertible notes news

1. Debt Financing · 2026-10-27 [VolitionRx prepays $500,000 on Lind note and defers two monthly payments](https://aibio.space/news/volitionrx-prepays-500-000-lind-note-defers-two-monthly-payments/) The remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more. [VNRX](https://aibio.space/companies/volitionrx/)
2. Debt Financing · 2026-10-26 [West Pharmaceutical enters $750 million revolver and $200 million term loan](https://aibio.space/news/west-pharmaceutical-enters-750-million-revolver-200-million-term-loan/) Bank of America, N.A. is administrative agent under the new unsecured credit agreement. The company repaid $130.0 million under its 2019 credit agreement. [WST](https://aibio.space/companies/west-pharmaceutical-services/)
3. Debt Financing · 2026-10-23 [China Resources Pharmaceutical issues RMB800 million third tranche of notes](https://aibio.space/news/china-resources-pharmaceutical-issues-rmb800-million-third-tranche/) A wholly owned subsidiary completed the third 2026 tranche of medium term notes, RMB800 million at 1.45% per annum over three years. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
4. Debt Financing · 2026-10-22 [Glucotrack sells secured convertible notes and warrants, with Dawson James as placement agent](https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/) The senior secured convertible notes carry a 22% original issue discount, 8% interest and a 9-month term. Dawson James Securities, Inc. is named as placement agent. [GCTK](https://aibio.space/companies/glucotrack/)
5. Debt Financing · 2026-10-19 [Integra LifeSciences sells $450 million of 9.500% senior secured notes, refinances credit facility](https://aibio.space/news/integra-lifesciences-sells-450-million-9-500-percent-senior-secured/) Integra refinanced a $1.3 billion revolver and a $775 million term loan with $450 million of 9.500% notes due 2033 and a $1.65 billion credit agreement, after reporting a 2025 net loss of $516.5 million. [IART](https://aibio.space/companies/integra-lifesciences/)
6. Debt Financing · 2026-10-16 [China Resources Pharmaceutical unit issues RMB900 million corporate bonds](https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb900-million-corporate/) A wholly owned subsidiary completed the second tranche of its 2026 corporate bonds in the PRC, RMB900 million at 1.48% per annum over three years. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
7. Debt Financing · 2026-10-16 [Clearmind Medicine to sell $2,000,000 of convertible notes for $1,800,000 in cash](https://aibio.space/news/clearmind-medicine-sell-2-000-000-convertible-notes-1-800-000-cash/) The sale draws on an agreement allowing up to $10,000,000 of convertible promissory notes. The company expects it to close on or before October 19, 2026. [CMND](https://aibio.space/companies/clearmind-medicine/)
8. Debt Financing · 2026-10-15 [Profusa issues $769,230.77 secured convertible note to Ascent Partners](https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/) The note carries 7% interest, converts at $4.28 a share and matures in October 2027. [PFSA](https://aibio.space/companies/profusa/)
9. Debt Financing · 2026-10-15 [OSR Health amends VXM01 license to allow up to $15,000,000 in convertible notes](https://aibio.space/news/osr-health-amends-vxm01-license-allow-up-15-000-000-convertible-notes/) Under an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option. [OSRH](https://aibio.space/companies/osr-health/)
10. Debt Financing · 2026-10-13 [ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million](https://aibio.space/news/adc-therapeutics-agrees-86-6-million-pipe-plans-loan-cut-50-0-million/) ADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30. [ADCT](https://aibio.space/companies/adc-therapeutics/)
11. Debt Financing · 2026-10-13 [CDT Equity gets $3,000,000 first tranche of $6,750,000 convertible note](https://aibio.space/news/cdt-equity-gets-3-000-000-first-tranche-6-750-000-convertible-note/) The first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026. [CDT](https://aibio.space/companies/cdt-equity/)
12. Debt Financing · 2026-10-09 [Integra LifeSciences prices $450,000,000 senior secured notes](https://aibio.space/news/integra-lifesciences-prices-450-000-000-senior-secured-notes/) The 9.500% notes are due 2033 and will help refinance the company's existing credit facilities. [IART](https://aibio.space/companies/integra-lifesciences/)
13. Debt Financing · 2026-10-09 [TuHURA Biosciences draws $650,000 more on Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line-2/) TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million. [HURA](https://aibio.space/companies/tuhura-biosciences/)
14. Debt Financing · 2026-10-09 [SS Innovations issues $21,025,000.00 secured convertible note](https://aibio.space/news/ss-innovations-issues-21-025-000-00-secured-convertible-note/) Growth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price. [SSII](https://aibio.space/companies/ss-innovations-international/)
15. Debt Financing · 2026-10-09 [Co-Diagnostics issues senior secured convertible note to J.J. Astor](https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/) The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027. [CODX](https://aibio.space/companies/diagnostics/)
16. Debt Financing · 2026-10-09 [Co-Diagnostics takes up to $3.1 million in secured convertible loans](https://aibio.space/news/co-diagnostics-takes-up-3-1-million-secured-convertible-loans/) J.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital. [CODX](https://aibio.space/companies/diagnostics/)
17. Debt Financing · 2026-10-08 [Revolution Medicines borrows $250.0 million under Royalty Pharma loan](https://aibio.space/news/revolution-medicines-borrows-250-0-million-under-royalty-pharma-loan/) Revolution Medicines borrowed $250.0 million on October 8, 2026, under a senior secured term loan with Royalty Pharma Development Funding, LLC. The loan carries a floating rate of three-month Term SOFR plus 5.75%. [RVMD](https://aibio.space/companies/revolution-medicines/)
18. Debt Financing · 2026-10-08 [X4 Pharmaceuticals replaces loan with up to $150 million K2 facility](https://aibio.space/news/x4-pharmaceuticals-replaces-loan-up-150-million-k2-facility/) The first $80 million tranche repaid the prior loan in full, including $75 million of principal. [XFOR](https://aibio.space/companies/x4-pharmaceuticals/)
19. Debt Financing · 2026-10-08 [X4 Pharmaceuticals signs up to $150 million senior loan with K2 HealthVentures](https://aibio.space/news/x4-pharmaceuticals-signs-up-150-million-senior-loan-k2-healthventures/) The first $80 million tranche repaid $75 million of principal and fees owed under the prior loan. Another $70 million may be available at X4's request, subject to K2HV approval. [XFOR](https://aibio.space/companies/x4-pharmaceuticals/)
20. Debt Financing · 2026-10-07 [CERo agrees to sell operating unit to SRX Global](https://aibio.space/news/cero-agrees-sell-operating-unit-srx-global/) CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77. [CERO](https://aibio.space/companies/cero-therapeutics/)
21. Debt Financing · 2026-10-07 [FibroBiologics sells $1,200,000 convertible debenture to Peak One](https://aibio.space/news/fibrobiologics-sells-1-200-000-convertible-debenture-peak-one/) FibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share. [FBLG](https://aibio.space/companies/fibrobiologics/)
22. Debt Financing · 2026-10-06 [Vaxcyte offers $500,000,000 of 1.50% convertible notes due 2032](https://aibio.space/news/vaxcyte-offers-500-000-000-1-50-percent-convertible-notes-due-2032/) Vaxcyte is selling common stock and pre-funded warrants alongside $500,000,000 of convertible senior notes due 2032, a day after reporting Phase 3 data for VAX-31. [PCVX](https://aibio.space/companies/vaxcyte/)
23. Debt Financing · 2026-10-06 [Nuo Therapeutics receives $325,000 second funding under loan](https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/) Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. [AURX](https://aibio.space/companies/nuo-therapeutics/)
24. Debt Financing · 2026-10-06 [Rocket Pharmaceuticals secures credit facility of up to $150 million](https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/) Hercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026. [RCKT](https://aibio.space/companies/rocket-pharmaceuticals/)[HTGC](https://aibio.space/companies/hercules-capital/)
25. Debt Financing · 2026-10-06 [Rocket Pharmaceuticals secures credit facility of up to $150 million from Hercules](https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/) Rocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029. [RCKT](https://aibio.space/companies/rocket-pharmaceuticals/)[HTGC](https://aibio.space/companies/hercules-capital/)
26. Debt Financing · 2026-10-04 [Profusa amends Ascent Partners convertible note terms](https://aibio.space/news/profusa-amends-ascent-partners-convertible-note-terms/) Ascent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026. [PFSA](https://aibio.space/companies/profusa/)
27. Debt Financing · 2026-09-30 [iTonic Holdings extends maturity of bank loan to March 2027](https://aibio.space/news/itonic-holdings-extends-maturity-bank-loan-march-2027/) Beijing Rural Commercial Bank is the lender. A director gave an unsecured personal guarantee for the loan without consideration, and the company held $779,367 in cash and cash equivalents at June 30, 2026. [ITOC](https://aibio.space/companies/itonic/)
28. Debt Financing · 2026-09-30 [Positron issues three promissory notes at 20% interest, with warrants](https://aibio.space/news/positron-issues-three-promissory-notes-20-percent-interest-warrants/) The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share. [POSC](https://aibio.space/companies/positron/)
29. Debt Financing · 2026-09-29 [Odyssey Health extends two note maturities to January 2027](https://aibio.space/news/odyssey-health-extends-two-note-maturities-january-2027/) Two notes held by LGH Investments, LLC and Peter J. D'Arruda now mature on January 31, 2027. All other terms stay the same, the filing says. [ODYY](https://aibio.space/companies/odyssey-health/)
30. Debt Financing · 2026-09-28 [TELA Bio gets lender consent to pause revenue covenant test](https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/) The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent. [TELA](https://aibio.space/companies/tela-bio/)
31. Debt Financing · 2026-09-28 [Glucotrack amends terms of senior secured convertible note](https://aibio.space/news/glucotrack-amends-terms-senior-secured-convertible-note/) The amendment makes the floor price a hard limit and requires any make-whole payment to be made in cash. Glucotrack had $1.1 million in cash and cash equivalents at June 30, 2026. [GCTK](https://aibio.space/companies/glucotrack/)
32. Debt Financing · 2026-09-28 [Celularity sells $11.01 million of secured convertible notes in deal of up to $25.0 million](https://aibio.space/news/celularity-sells-11-01-million-secured-convertible-notes-deal-up-25-0/) Celularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027. [CELU](https://aibio.space/companies/celularity/)
33. Debt Financing · 2026-09-23 [Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18](https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/) Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier. [JAZZ](https://aibio.space/companies/jazz-pharmaceuticals/)
34. Debt Financing · 2026-09-23 [IQVIA issues $2,000,000,000 of 6.375% senior notes due 2034](https://aibio.space/news/iqvia-issues-2-000-000-000-6-375-percent-senior-notes-due-2034/) The notes are governed by an indenture dated September 23, 2026, with U.S. Bank Trust Company, National Association, as trustee. [IQV](https://aibio.space/companies/iqvia/)
35. Debt Financing · 2026-09-23 [Viking Therapeutics sells $225,000,000 of 2.00% convertible notes due 2032](https://aibio.space/news/viking-therapeutics-sells-225-000-000-2-00-percent-convertible-notes/) Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are the underwriters' representatives. The initial conversion price is about $50.75 a share, and the company sold 7,857,143 common shares at $35.00 in a separate offering the same day. [VKTX](https://aibio.space/companies/viking-therapeutics/)
36. Debt Financing · 2026-09-23 [PROCEPT BioRobotics amends Canadian Imperial Bank term loan maturity](https://aibio.space/news/procept-biorobotics-amends-canadian-imperial-bank-term-loan-maturity/) The amendment extends the term loan maturity by one year, to the 72nd payment date after closing. PROCEPT BioRobotics paid a $26,000.00 extension fee. [PRCT](https://aibio.space/companies/procept-biorobotics/)
37. Debt Financing · 2026-09-23 [QuidelOrtho amends credit agreement and resets covenant levels to 2029](https://aibio.space/news/quidelortho-amends-credit-agreement-resets-covenant-levels-2029/) Bank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026. [QDEL](https://aibio.space/companies/quidelortho/)
38. Debt Financing · 2026-09-23 [Bayer places 2 billion euros of hybrid bonds](https://aibio.space/news/bayer-places-2-billion-euros-hybrid-bonds/) Two tranches, with non-call periods of six and nine years, raise 2 billion euros for general corporate purposes. [BAYN](https://aibio.space/companies/bayer/)
39. Debt Financing · 2026-09-22 [Halozyme Therapeutics sells $1,500.0 million of 1.50% convertible notes](https://aibio.space/news/halozyme-therapeutics-sells-1-500-0-million-1-50-percent-convertible/) The Bank of New York Mellon Trust Company, N.A. is trustee. The company used $187.5 million of the net proceeds on capped calls and expects to buy back older convertible notes, and its cash and cash equivalents were $163.1 million at June 30, 2026. [HALO](https://aibio.space/companies/halozyme-therapeutics/)
40. Debt Financing · 2026-09-21 [Insulet amends credit agreement, refinancing $475 million in term loans](https://aibio.space/news/insulet-amends-credit-agreement-refinancing-475-million-term-loans/) Morgan Stanley Senior Funding, Inc. is administrative agent. The margin on the refinanced term loans falls 0.25%, and cash and cash equivalents were $534.9 million at June 30, 2026, down from $716.1 million at the end of 2025. [PODD](https://aibio.space/companies/insulet/)
41. Debt Financing · 2026-09-21 [TuHURA Biosciences draws another $650,000 on Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-another-650-000-parkview-credit-line/) Parkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026. [HURA](https://aibio.space/companies/tuhura-biosciences/)
42. Debt Financing · 2026-09-18 [Endovia closes $510,000 secured convertible note from C/M Capital](https://aibio.space/news/endovia-closes-510-000-secured-convertible-note-c-m-capital/) C/M Capital Master Fund, LP is the investor. The $510,000 note converts at the lower of $1.75 and $0.01 above the closing price, and the company had $242,702 in cash and cash equivalents at June 30, 2026. [EDVA](https://aibio.space/companies/endovia-health-sciences/)
43. Debt Financing · 2026-09-17 [Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants](https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/) A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. [QNTM](https://aibio.space/companies/quantum-biopharma/)
44. Debt Financing · 2026-09-16 [Halozyme plans $1.05 billion convertible notes offering](https://aibio.space/news/halozyme-plans-1-05-billion-convertible-notes-offering/) Halozyme intends to offer $1.05 billion of convertible senior notes due 2033, with a 13-day option for up to $150 million more. Rate and conversion terms will be set at pricing, and the release names no bank. [HALO](https://aibio.space/companies/halozyme-therapeutics/)
45. Debt Financing · 2026-09-16 [Profusa sells senior secured convertible note to Ascent Partners Fund](https://aibio.space/news/profusa-sells-senior-secured-convertible-note-ascent-partners-fund/) Ascent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026. [PFSA](https://aibio.space/companies/profusa/)
46. Debt Financing · 2026-09-14 [MindWalk signs binding $30 million credit facility term sheet](https://aibio.space/news/mindwalk-signs-binding-30-million-credit-facility-term-sheet/) MindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed. [HYFT](https://aibio.space/companies/mindwalk/)
47. Debt Financing · 2026-09-14 [TuHURA Biosciences makes $650,000 draw on Parkview credit line](https://aibio.space/news/tuhura-biosciences-makes-650-000-draw-parkview-credit-line/) TuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026. [HURA](https://aibio.space/companies/tuhura-biosciences/)
48. Debt Financing · 2026-09-14 [CDT Equity issues $2,126,250 secured convertible note to J.J. Astor & Co.](https://aibio.space/news/cdt-equity-issues-2-126-250-secured-convertible-note-j-j-astor-co/) The note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor. [CDT](https://aibio.space/companies/cdt-equity/)
49. Debt Financing · 2026-09-11 [Glucotrack issues secured convertible notes and warrants in private placement](https://aibio.space/news/glucotrack-issues-secured-convertible-notes-warrants-private-placement/) The nine-month notes carry 8% interest and a 22% original issue discount, with Dawson James Securities, Inc. as placement agent and an exchange cap of 19.99%. [GCTK](https://aibio.space/companies/glucotrack/)
50. Debt Financing · 2026-09-10 [Cerenome gets up to $20 million royalty-based facility from 3i, LP](https://aibio.space/news/cerenome-gets-up-20-million-royalty-based-facility-3i-lp/) Cerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028. [CNSY](https://aibio.space/companies/cerenome/)
51. Debt Financing · 2026-09-10 [Karyopharm gets forbearance after missed loan and note payments](https://aibio.space/news/karyopharm-gets-forbearance-after-missed-loan-note-payments/) Lenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers. [KPTI](https://aibio.space/companies/karyopharm-therapeutics/)
52. Debt Financing · 2026-09-09 [Tenon Medical repays convertible notes ahead of September 11 maturity](https://aibio.space/news/tenon-medical-repays-convertible-notes-ahead-september-11-maturity/) Tenon repaid in full original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, issued March 11, 2026. The release names no noteholder or agent. [TNON](https://aibio.space/companies/tenon-medical/)
53. Debt Financing · 2026-09-04 [Intellia Therapeutics gets up to $400 million term loan from OrbiMed](https://aibio.space/news/intellia-therapeutics-gets-up-400-million-term-loan-orbimed/) Intellia Therapeutics will receive $75 million at closing under the facility. Up to $225 million more depends mainly on milestones for lonvo-z. [NTLA](https://aibio.space/companies/intellia-therapeutics/)
54. Debt Financing · 2026-09-03 [Hepion Pharmaceuticals issues $500,000 secured convertible note to Gravitas](https://aibio.space/news/hepion-pharmaceuticals-issues-500-000-secured-convertible-note/) The note bears 8% interest payable in kind and matures September 3, 2027. It converts at $0.04 per share after stockholders approve more authorized shares. [HEPA](https://aibio.space/companies/hepion-pharmaceuticals/)
55. Debt Financing · 2026-09-03 [Senti Biosciences unit sells $2.0 million in convertible notes to NSG](https://aibio.space/news/senti-biosciences-unit-sells-2-0-million-convertible-notes-nsg/) The notes were issued under an April 27, 2026 purchase agreement, as amended on September 1, 2026. A separate $2.5 million equity commitment was signed the same day. [SNTI](https://aibio.space/companies/senti-biosciences/)
56. Debt Financing · 2026-09-02 [TuHURA Biosciences borrows $1,500,000 under Parkview revolving facility](https://aibio.space/news/tuhura-biosciences-borrows-1-500-000-under-parkview-revolving-facility/) The company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031. [HURA](https://aibio.space/companies/tuhura-biosciences/)
57. Debt Financing · 2026-09-02 [VolitionRx gets Lind waiver for ATM sales above $10 million](https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/) Lind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026. [VNRX](https://aibio.space/companies/volitionrx/)
58. Debt Financing · 2026-09-01 [Profusa sells another senior secured convertible note to Ascent](https://aibio.space/news/profusa-sells-another-senior-secured-convertible-note-ascent/) The note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser. [PFSA](https://aibio.space/companies/profusa/)
59. Debt Financing · 2026-09-01 [KPC gets registration for RMB1 billion medium term notes](https://aibio.space/news/kpc-gets-registration-rmb1-billion-medium-term-notes/) A non-wholly owned subsidiary of China Resources Pharmaceutical received a two-year registration for up to RMB1 billion of medium term notes. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
60. Debt Financing · 2026-08-31 [AIM ImmunoTech satisfies Streeterville note in full through share exchanges](https://aibio.space/news/aim-immunotech-satisfies-streeterville-note-full-through-share/) AIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026. [AIM](https://aibio.space/companies/aim-immunotech/)
61. Debt Financing · 2026-08-31 [PDS Biotechnology amends $6,000,000 promissory note](https://aibio.space/news/pds-biotechnology-amends-6-000-000-promissory-note/) PDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment. [PDSB](https://aibio.space/companies/pds-biotechnology/)
62. Debt Financing · 2026-08-31 [Kyntra Bio cuts royalty financing cap to $65 million](https://aibio.space/news/kyntra-bio-cuts-royalty-financing-cap-65-million/) Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum payments and making a $42.6 million upfront payment. [KYNB](https://aibio.space/companies/kyntra-bio/)
63. Debt Financing · 2026-08-31 [CDT Equity issues $541,620 senior secured convertible note to J.J. Astor](https://aibio.space/news/cdt-equity-issues-541-620-senior-secured-convertible-note-j-j-astor/) The note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares. [CDT](https://aibio.space/companies/cdt-equity/)
64. Debt Financing · 2026-08-28 [Moderna sells $3.0 billion of zero-coupon convertible notes after upsized pricing](https://aibio.space/news/moderna-sells-3-0-billion-zero-coupon-convertible-notes-after-upsized/) The notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business. [MRNA](https://aibio.space/companies/moderna/)
65. Debt Financing · 2026-08-28 [InSilico Medicine plans US$305 million convertible bond sale](https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/) The company agreed on August 27, 2026 to issue convertible bonds with an initial conversion price of HK$58.07 per share. [3696](https://aibio.space/companies/insilico-medicine-cayman-topco/)
66. Debt Financing · 2026-08-27 [Moderna plans $2.0 billion convertible notes private placement](https://aibio.space/news/moderna-plans-2-0-billion-convertible-notes-private-placement/) Moderna said it intends to sell $2.0 billion of notes due 2032, with an option for up to $300.0 million more. It would also enter capped call transactions to reduce potential dilution. [MRNA](https://aibio.space/companies/moderna/)
67. Debt Financing · 2026-08-27 [CERo Therapeutics consolidates older notes into secured SRX Global loan](https://aibio.space/news/cero-therapeutics-consolidates-older-notes-secured-srx-global-loan/) The note combines earlier notes and lets SRX advance up to $6,000,000 in total at 10% interest. Principal and interest are due October 15, 2026. [CERO](https://aibio.space/companies/cero-therapeutics/)
68. Debt Financing · 2026-08-27 [Pharmaron agrees to issue RMB2,180 million convertible bonds](https://aibio.space/news/pharmaron-agrees-issue-rmb2-180-million-convertible-bonds/) Pharmaron Beijing signed an agreement on August 26, 2026 for convertible bonds with an initial conversion price of HK$36.08 per H share. [300759](https://aibio.space/companies/pharmaron-beijing/)
69. Debt Financing · 2026-08-26 [Jazz plans $1.0 billion exchangeable notes offering with share buyback](https://aibio.space/news/jazz-plans-1-0-billion-exchangeable-notes-offering-share-buyback/) Jazz Investments I Limited plans to sell $1.0 billion of exchangeable notes due 2032. Jazz also expects to buy back up to $225.0 million of its ordinary shares from note purchasers. [JAZZ](https://aibio.space/companies/jazz-pharmaceuticals/)
70. Debt Financing · 2026-08-24 [BioXcel takes $1,250,000 in additional term loans from its lenders](https://aibio.space/news/bioxcel-takes-1-250-000-additional-term-loans-lenders/) The amendment also lowers the minimum cash liquidity covenant to $250,000 and sets an August 31, 2026 deadline for a transaction acceptable to the lenders. [BTAI](https://aibio.space/companies/bioxcel-therapeutics-btai/)
71. Debt Financing · 2026-08-21 [Nexalin issues $1,170,000.00 promissory note to Streeterville Capital](https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/) The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. [NXL](https://aibio.space/companies/nexalin-technology/)
72. Debt Financing · 2026-08-21 [BCAL Diagnostics details convertible note draws under its $10 million facility](https://aibio.space/news/bcal-diagnostics-details-convertible-note-draws-under-10-million/) After raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity. [BDX](https://aibio.space/companies/becton-dickinson/)
73. Debt Financing · 2026-08-21 [Imugene amends CVI convertible notes and issues new warrants](https://aibio.space/news/imugene-amends-cvi-convertible-notes-issues-new-warrants/) A$2.1 million of existing notes is redeemed and replaced by new zero-coupon notes, and the remaining notes amortise in five instalments. [IMU](https://aibio.space/companies/imugene/)
74. Debt Financing · 2026-08-18 [ICON plc issues $2.15 billion of senior unsecured notes](https://aibio.space/news/icon-plc-issues-2-15-billion-senior-unsecured-notes/) The notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes. [ICLR](https://aibio.space/companies/icon/)
75. Debt Financing · 2026-08-18 [Baxter raises note tender offer cap to $600 million after early results](https://aibio.space/news/baxter-raises-note-tender-offer-cap-600-million-after-early-results/) Holders tendered $756,712,000 of the 2.539% notes due 2032 by the early tender time. The offer cap rose from $500 million to $600 million. [BAX](https://aibio.space/companies/baxter-international/)
76. Debt Financing · 2026-08-17 [Coherus Oncology takes $55,000,000 senior secured term loan to refinance debt](https://aibio.space/news/coherus-oncology-takes-55-000-000-senior-secured-term-loan-refinance/) Innovatus Life Sciences Lending Fund I, LP, is collateral agent on a loan that replaces an existing term loan and runs to August 2031, with interest-only payments for an initial 36 months. [CHRS](https://aibio.space/companies/coherus-oncology/)
77. Debt Financing · 2026-08-14 [Trinity Biotech amends Perceptive term loan, adding about $2.5 million](https://aibio.space/news/trinity-biotech-amends-perceptive-term-loan-adding-about-2-5-million/) The amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million. [TRIB](https://aibio.space/companies/trinity-biotech/)
78. Debt Financing · 2026-08-14 [Senti Biosciences unit sells $4.0 million of convertible notes to Celadon](https://aibio.space/news/senti-biosciences-unit-sells-4-0-million-convertible-notes-celadon/) The notes were issued under an April 27, 2026 purchase agreement. The filing also ties the company to a potential merger with a contingent value right that could pay up to $60.0 million in cash. [SNTI](https://aibio.space/companies/senti-biosciences/)
79. Debt Financing · 2026-08-13 [OPKO issues $125,000,000 in additional senior secured notes](https://aibio.space/news/opko-issues-125-000-000-additional-senior-secured-notes/) The notes mature in July 2044 and are secured by royalty payments that EirGen Pharma Limited receives on mazdutide. HCR Injection SPV, LLC serves as agent. [OPK](https://aibio.space/companies/opko-health/)
80. Debt Financing · 2026-08-13 [Positron arranges $2,000,000 line of credit at 12% from investor George Ortiz](https://aibio.space/news/positron-arranges-2-000-000-line-credit-12-percent-investor-george/) The note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues. [POSC](https://aibio.space/companies/positron/)
81. Debt Financing · 2026-08-12 [Alkermes amends term loan credit agreement, cutting interest spreads](https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/) JPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%. [ALKS](https://aibio.space/companies/alkermes/)
82. Debt Financing · 2026-08-12 [Agenus extends Ocean 1181 loan maturity to November 2029](https://aibio.space/news/agenus-extends-ocean-1181-loan-maturity-november-2029/) The loan principal stays at $24,750,000 and the rate stays at 13.0%. The $247,500 extension fee is paid half in cash and half in shares. [AGEN](https://aibio.space/companies/agenus/)
83. Debt Financing · 2026-08-12 [Profusa issues $714,285.72 senior secured convertible note](https://aibio.space/news/profusa-issues-714-285-72-senior-secured-convertible-note/) The note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor. [PFSA](https://aibio.space/companies/profusa/)
84. Debt Financing · 2026-08-11 [Enlivex amends $21.0 million Lind note and resets conversion price](https://aibio.space/news/enlivex-amends-21-0-million-lind-note-resets-conversion-price/) Enlivex deleted a market capitalization default from its Lind note and revised conversion and prepayment terms. Outstanding principal rose to $19.2 million. [ENLV](https://aibio.space/companies/enlivex/)
85. Debt Financing · 2026-08-10 [BioXcel amends Oaktree credit agreement, sets August 21 deadline](https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-sets-august-21-deadline/) Oaktree Fund Administration, LLC is administrative agent. The amendment requires definitive transaction agreements by August 21, 2026 and sets the minimum liquidity amount at $3,000,000 from August 10, 2026. [BTAI](https://aibio.space/companies/bioxcel-therapeutics-btai/)
86. Debt Financing · 2026-08-10 [OS Therapies sells up to $10,000,000 of senior secured convertible notes](https://aibio.space/news/os-therapies-sells-up-10-000-000-senior-secured-convertible-notes/) The first closing on August 10, 2026 covered $5,000,000 of units, including a bridge note conversion, and the second tranche is optional for each purchaser. [OSTX](https://aibio.space/companies/os-therapies/)
87. Debt Financing · 2026-08-10 [Aspire closes $30.0 million cash acquisition and enters $22.5 million revolver](https://aibio.space/news/aspire-closes-30-0-million-cash-acquisition-enters-22-5-million/) The senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender. [ASBP](https://aibio.space/companies/aspire-lakewood/)
88. Debt Financing · 2026-08-07 [TuHURA Biosciences draws $650,000 more on its Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line/) The draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031. [HURA](https://aibio.space/companies/tuhura-biosciences/)
89. Debt Financing · 2026-08-06 [ICON plc subsidiary prices senior notes to repay bridge and term loans](https://aibio.space/news/icon-plc-subsidiary-prices-senior-notes-repay-bridge-term-loans/) ICON plc said its subsidiary priced three series of senior unsecured notes. Proceeds are meant to repay its bridge facility, senior secured term loans and 2027 notes. [ICLR](https://aibio.space/companies/icon/)
90. Debt Financing · 2026-08-04 [Glucotrack adds $3,500,000 to secured convertible bridge financing](https://aibio.space/news/glucotrack-adds-3-500-000-secured-convertible-bridge-financing/) Glucotrack issued follow-on senior secured convertible notes with a $4,487,179 face amount and sold pre-funded warrants in an interim private placement. [GCTK](https://aibio.space/companies/glucotrack/)
91. Debt Financing · 2026-08-03 [Supernus and Indivior plan merger backed by $650 million Citibank loan](https://aibio.space/news/supernus-indivior-plan-merger-backed-650-million-citibank-loan/) Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026. [SUPN](https://aibio.space/companies/supernus-pharmaceuticals/)[INDV](https://aibio.space/companies/indivior-pharmaceuticals/)
92. Debt Financing · 2026-08-03 [Amneal reprices $2.039 billion term loan and adds $45.2 million](https://aibio.space/news/amneal-reprices-2-039-billion-term-loan-adds-45-2-million/) Amneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032. [AMRX](https://aibio.space/companies/amneal-pharmaceuticals/)
93. Debt Financing · 2026-08-03 [Autolus issues first $75 million under up to $250 million Perceptive facility](https://aibio.space/news/autolus-issues-first-75-million-under-up-250-million-perceptive/) Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million. [AUTL](https://aibio.space/companies/autolus-therapeutics/)
94. Debt Financing · 2026-07-31 [BioXcel amends Oaktree credit agreement and defers payment](https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-defers-payment/) BioXcel's Eleventh Amendment moves a $9,016,914.47 payment to August 31, 2026, lowers the minimum liquidity amount to $6,250,000 and requires definitive transaction agreements by August 10, 2026. [BTAI](https://aibio.space/companies/bioxcel-therapeutics-btai/)
95. Debt Financing · 2026-07-31 [CDT Equity raises J.J. Astor note to $2,266,650 at 19% interest](https://aibio.space/news/cdt-equity-raises-j-j-astor-note-2-266-650-19-percent-interest/) CDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock. [CDT](https://aibio.space/companies/cdt-equity/)
96. Debt Financing · 2026-07-31 [ProPhase Labs issues $2,085,000 senior secured convertible note](https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/) ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027. [PRPH](https://aibio.space/companies/prophase-labs/)
97. Debt Financing · 2026-07-31 [Aiforia signs EUR 20 million venture debt with EIB](https://aibio.space/news/aiforia-signs-eur-20-million-venture-debt-eib/) The binding agreement with the European Investment Bank has three tranches and covenants tied to management changes.
98. Debt Financing · 2026-07-30 [Annexon secures credit facility of up to $200 million from Oxford Finance](https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/) Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. [ANNX](https://aibio.space/companies/annexon/)
99. Debt Financing · 2026-07-29 [Accuray gets lender waiver of defaults under financing agreement](https://aibio.space/news/accuray-gets-lender-waiver-defaults-under-financing-agreement/) Accuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval. [ARAY](https://aibio.space/companies/accuray/)
100. Debt Financing · 2026-07-29 [China Resources Pharmaceutical issues RMB1 billion second tranche of notes](https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-second-tranche/) A wholly owned subsidiary completed the second 2026 tranche of medium term notes, RMB1 billion at 1.52% per annum over three years. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
101. Debt Financing · 2026-07-28 [American Shared Hospital Services signs forbearance with Fifth Third Bank](https://aibio.space/news/american-shared-hospital-services-signs-forbearance-fifth-third-bank/) A third amendment to the credit agreement with Fifth Third Bank, National Association, sets a standstill period that runs to June 30, 2027. [AMS](https://aibio.space/companies/american-shared-hospital-services/)
102. Debt Financing · 2026-07-28 [Grifols refinances all 2027 maturities with about €3 billion term loan](https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/) Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. [GRF](https://aibio.space/companies/grifols-s-a/)
103. Debt Financing · 2026-07-28 [TuHURA Biosciences draws $1,500,000 on its Parkview revolving credit facility](https://aibio.space/news/tuhura-biosciences-draws-1-500-000-parkview-revolving-credit-facility/) TuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender. [HURA](https://aibio.space/companies/tuhura-biosciences/)
104. Debt Financing · 2026-07-27 [Profusa expects about $7 million convertible note alongside diagnostics deal](https://aibio.space/news/profusa-expects-about-7-million-convertible-note-alongside-diagnostics/) Profusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount. [PFSA](https://aibio.space/companies/profusa/)
105. Debt Financing · 2026-07-27 [BiomX extends $1,250,000 note to November 1, 2026](https://aibio.space/news/biomx-extends-1-250-000-note-november-1-2026/) BiomX extended a $1,250,000 promissory note held by Water IO Ltd. to November 1, 2026, after a $250,000 payment. The remaining principal is due in four monthly installments of $250,000, and accrued interest is to be settled in 800,000 shares of common stock if approvals arrive.
106. Debt Financing · 2026-07-22 [China Resources Pharmaceutical issues RMB1 billion medium term notes](https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/) A wholly owned subsidiary completed the first tranche of its 2026 medium term notes on 21 July 2026, at 1.53% per annum over 3 years. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
107. Debt Financing · 2026-07-17 [Healthy Extracts issues $258,750 promissory note to Labrys Fund II](https://aibio.space/news/healthy-extracts-issues-258-750-promissory-note-labrys-fund-ii/) Healthy Extracts Inc. issued a one-year promissory note with a principal amount of $258,750 to LABRYS FUND II, L.P. under an agreement dated July 17, 2026. The company received a net amount of $225,000, minus expenses. [HYEX](https://aibio.space/companies/healthy-extracts/)
108. Debt Financing · 2026-07-17 [Xeris completes note exchange and conversion; no 2028 convertible notes remain](https://aibio.space/news/xeris-completes-note-exchange-conversion-no-2028-convertible-notes/) Holders swapped about $23 million of 8.00% notes for about 5.0 million shares and about $23 million in cash. A separate holder converted $10.5 million of notes into about 3.6 million shares. [XERS](https://aibio.space/companies/xeris-biopharma/)
109. Debt Financing · 2026-07-16 [Aditxt amends secured note purchase deal at Ignite Proteomics](https://aibio.space/news/aditxt-amends-secured-note-purchase-deal-ignite-proteomics/) Aditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged. [ADTX](https://aibio.space/companies/aditxt/)
110. Debt Financing · 2026-07-16 [Inhibrx expands Oxford Finance facility to $500.0 million](https://aibio.space/news/inhibrx-expands-oxford-finance-facility-500-0-million/) Inhibrx's Oxford Finance facility now totals up to $500.0 million. The company funded $100.0 million at signing, and up to $225.0 million more depends on the lenders' discretion. [INBX](https://aibio.space/companies/inhibrx-biosciences/)
111. Debt Financing · 2026-07-16 [Inhibrx expands Oxford Finance credit facility to up to $500.0 million](https://aibio.space/news/inhibrx-expands-oxford-finance-credit-facility-up-500-0-million/) A second amendment adds a tranche of up to $325.0 million, of which $100.0 million was funded at signing. The lenders received warrants for 21,457 shares at $93.21 per share. [INBX](https://aibio.space/companies/inhibrx-biosciences/)
112. Debt Financing · 2026-07-15 [Prestige Brands sells $400.0 million of 6.250% senior notes due 2034](https://aibio.space/news/prestige-brands-sells-400-0-million-6-250-percent-senior-notes-due/) Prestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026. [PBH](https://aibio.space/companies/prestige-consumer-healthcare/)
113. Debt Financing · 2026-07-15 [Bayer places 5 billion U.S. dollars of bonds in five tranches](https://aibio.space/news/bayer-places-5-billion-u-s-dollars-bonds-five-tranches/) Bayer US Finance LLC issues the notes, guaranteed by Bayer AG, with maturities between 5 and 30 years. [BAYN](https://aibio.space/companies/bayer/)
114. Debt Financing · 2026-07-15 [Medincell secures €28 million in non-dilutive loans](https://aibio.space/news/medincell-secures-28-million-non-dilutive-loans/) The €28 million of bank loans has a five-year maturity and no covenants, and €20 million of the EIB facility is being repaid early, though the remaining EIB balance still comes due in July 2028. [MEDCL](https://aibio.space/companies/medincell/)
115. Debt Financing · 2026-07-15 [Neurotech secures $3.15 million secured loan](https://aibio.space/news/neurotech-secures-3-15-million-secured-loan/) The loan is secured against refundable R&D tax incentive offsets for FY2026 and FY2027 and will help fund Phase III studies in ASD.
116. Debt Financing · 2026-07-14 [CERo Therapeutics expands SRX Global convertible note to $2,085,200](https://aibio.space/news/cero-therapeutics-expands-srx-global-convertible-note-2-085-200/) CERo Therapeutics expanded its convertible note with SRX Global to $2,085,200. The note carries 10% interest, matures May 28, 2027, and converts at the lesser of $0.05 and 80% of recent trading lows. [CERO](https://aibio.space/companies/cero-therapeutics/)
117. Debt Financing · 2026-07-10 [Anika Therapeutics amends $50.0 million Bank of America revolving credit line](https://aibio.space/news/anika-therapeutics-amends-50-0-million-bank-america-revolving-credit/) Anika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets. [ANIK](https://aibio.space/companies/anika-therapeutics/)
118. Debt Financing · 2026-07-10 [Kestra Medical draws $75.0 million from up to $200.0 million term loan](https://aibio.space/news/kestra-medical-draws-75-0-million-up-200-0-million-term-loan/) Kestra Medical drew $75.0 million from a facility of up to $200.0 million. The Tranche A loan funded on July 10, 2026, and repaid a prior loan from Perceptive Credit Holdings IV, LP. [KMTS](https://aibio.space/companies/kestra-medical-technologies/)
119. Debt Financing · 2026-07-08 [Kyverna amends $150 million Oxford Finance loan facility](https://aibio.space/news/kyverna-amends-150-million-oxford-finance-loan-facility/) Kyverna extended availability of $15.0 million in remaining Term A Loans to December 31, 2026, for a $187,500 upfront fee. Further changes to the facility apply only if the company draws the full $15.0 million. [KYTX](https://aibio.space/companies/kyverna-therapeutics/)
120. Debt Financing · 2026-07-08 [Evofem Biosciences issues $706,304 subordinated note to HUB Cyber Security](https://aibio.space/news/evofem-biosciences-issues-706-304-subordinated-note-hub-cyber-security/) Evofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126. [EVFM](https://aibio.space/companies/evofem-biosciences/)
121. Debt Financing · 2026-07-06 [BioXcel amends its credit agreement and forms a strategic process committee](https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/) The Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date. [BTAIQ](https://aibio.space/companies/bioxcel-therapeutics-btaiq/)
122. Debt Financing · 2026-07-06 [Aspira Women's Health takes $1,050,000 secured subordinated loan](https://aibio.space/news/aspira-womens-health-takes-1-050-000-secured-subordinated-loan/) Aspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan. [AWHL](https://aibio.space/companies/aspira-women-s-health/)
123. Debt Financing · 2026-07-06 [Cynata takes $600,000 loan secured against R&D TI rebate](https://aibio.space/news/cynata-takes-600-000-loan-secured-against-r-d-ti-rebate/) The $600,000 loan is secured against an expected R&D tax rebate of approximately $1.7m and the company's assets, and falls due by 30 September 2026 unless extended. [CYP](https://aibio.space/companies/cynata-therapeutics/)
124. Debt Financing · 2026-07-06 [Prestige Consumer Healthcare draws $95.0 million term loan to fund LaCorium acquisition](https://aibio.space/news/prestige-consumer-healthcare-draws-95-0-million-term-loan-fund/) The company's subsidiary drew $95,000,000 on July 1, 2026. The 8-K also notes a $400,000,000 private offering of senior unsecured notes due 2034 whose pricing a July 6, 2026 press release announced. [PBH](https://aibio.space/companies/prestige-consumer-healthcare/)
125. Debt Financing · 2026-07-06 [Nuvation Bio issues $37.5 million more convertible notes, offering totals $287.5 million](https://aibio.space/news/nuvation-bio-issues-37-5-million-more-convertible-notes-offering/) Nuvation Bio issued $37.5 million more of its 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters exercised their option in full. The offering now totals $287.5 million, with estimated net proceeds of about $277.6 million, and the notes can be settled in cash, shares or both at the company's choice. [NUVB](https://aibio.space/companies/nuvation-bio/)
126. Debt Financing · 2026-07-06 [Nuvation Bio's convertible notes offering reaches $287.5 million after greenshoe](https://aibio.space/news/nuvation-bios-convertible-notes-offering-reaches-287-5-million-after/) Nuvation Bio's underwriters exercised in full an option for $37.5 million more of 0.75% convertible senior notes due 2032, lifting the offering to $287.5 million. Net proceeds are estimated at $277.6 million, and the capped calls bought with them cost about $2.2 million. [NUVB](https://aibio.space/companies/nuvation-bio/)
127. Debt Financing · 2026-07-02 [Omeros expects to close $16.0 million note repurchase, agrees to $14.5 million more](https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/) Omeros expects to close a $16.0 million principal repurchase of its 9.50% convertible notes due 2029, and agreed to buy up to $14.5 million more. The repurchases would leave about $40.3 million of notes outstanding, and the company may replace the cash with debt that is not convertible into equity. [OMER](https://aibio.space/companies/omeros/)
128. Debt Financing · 2026-07-02 [Ardelyx draws $50.0 million Term F Loan under SLR Investment Corp. loan agreement, maturing 2030](https://aibio.space/news/ardelyx-draws-50-0-million-term-f-loan-under-slr-investment-corp-loan/) Ardelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030. [ARDX](https://aibio.space/companies/ardelyx/)
129. Debt Financing · 2026-07-01 [Viatris closes ¥40,000,000,000 unsecured term loan with Mizuho Bank](https://aibio.space/news/viatris-closes-40-000-000-000-unsecured-term-loan-mizuho-bank/) Viatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025. [VTRS](https://aibio.space/companies/viatris/)
130. Debt Financing · 2026-07-01 [Alvotech secures $75 million term loan from GoldenTree funds](https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/) Alvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025. [ALVO](https://aibio.space/companies/alvotech/)
131. Debt Financing · 2026-07-01 [Fresenius issues €1 billion in dual-tranche bonds](https://aibio.space/news/fresenius-issues-1-billion-dual-tranche-bonds/) Two €500 million tranches, due in 2031 and 2034, will fund general corporate purposes, including refinancing. [FRE](https://aibio.space/companies/fresenius/)
132. Debt Financing · 2026-06-30 [Lifeward amends senior secured convertible notes tied to Oramed](https://aibio.space/news/lifeward-amends-senior-secured-convertible-notes-tied-oramed/) The notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher. [LFWD](https://aibio.space/companies/lifeward/)
133. Debt Financing · 2026-06-30 [Bespoke Extracts extends senior secured notes to August 14, 2026](https://aibio.space/news/bespoke-extracts-extends-senior-secured-notes-august-14-2026/) The amendment moves the maturity of $410,000 in notes from June 30 to August 14, 2026, raises the rate to 17% from July 1 and requires extension shares. [BSPK](https://aibio.space/companies/bespoke-extracts/)
134. Debt Financing · 2026-06-30 [TuHURA Biosciences borrows $1,900,000 more under Parkview credit line](https://aibio.space/news/tuhura-biosciences-borrows-1-900-000-more-under-parkview-credit-line/) TuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral. [HURA](https://aibio.space/companies/tuhura-biosciences/)
135. Debt Financing · 2026-06-30 [OS Therapies signs $10 million secured convertible note with Leonite Fund](https://aibio.space/news/os-therapies-signs-10-million-secured-convertible-note-leonite-fund/) The company calls it a line of credit backed by UK tax credits. It drew $1.6 million first, mainly for OST-HER2 manufacturing. [OSTX](https://aibio.space/companies/os-therapies/)
136. Debt Financing · 2026-06-30 [CDT Equity closes second tranche of its $1,460,000 convertible loan](https://aibio.space/news/cdt-equity-closes-second-tranche-1-460-000-convertible-loan/) J.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026. [CDT](https://aibio.space/companies/cdt-equity/)
137. Debt Financing · 2026-06-29 [Agenus extends maturity of $5.09 million in notes](https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/) Agenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to June 25, 2031. The filing does not describe new cash from the deal. [AGEN](https://aibio.space/companies/agenus/)
138. Debt Financing · 2026-06-29 [Celularity takes $1,000,000 secured loan from Barach family trust](https://aibio.space/news/celularity-takes-1-000-000-secured-loan-barach-family-trust/) Celularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default. [CELU](https://aibio.space/companies/celularity/)
139. Debt Financing · 2026-06-29 [Ardelyx draws $50.0 million term loan from SLR Investment Corp.](https://aibio.space/news/ardelyx-draws-50-0-million-term-loan-slr-investment-corp/) Ardelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash. [ARDX](https://aibio.space/companies/ardelyx/)
140. Debt Financing · 2026-06-26 [Shoulder Innovations takes $15.0 million Stifel term loan, repays Trinity](https://aibio.space/news/shoulder-innovations-takes-15-0-million-stifel-term-loan-repays/) Shoulder Innovations signed a $15.0 million senior secured term loan with Stifel Bank on June 26, 2026, and used it to repay Trinity Capital. The $30.0 million asset-based revolver was undrawn at closing. [SI](https://aibio.space/companies/shoulder-innovations/)
141. Debt Financing · 2026-06-26 [China Resources Pharmaceutical unit issues RMB2 billion corporate bonds](https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/) A non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
142. Debt Financing · 2026-06-25 [ALX Oncology closes up to $50,000,000 HSBC term loan facility](https://aibio.space/news/alx-oncology-closes-up-50-000-000-hsbc-term-loan-facility/) ALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones. [ALXO](https://aibio.space/companies/alx-oncology/)
143. Debt Financing · 2026-06-25 [Disc Medicine draws $30,000,000 and extends Hercules loan draw periods](https://aibio.space/news/disc-medicine-draws-30-000-000-extends-hercules-loan-draw-periods/) A First Amendment to the Hercules loan splits the remaining $50,000,000 tranche and extends later draw deadlines into 2027 and 2028. [IRON](https://aibio.space/companies/disc-medicine/)
144. Debt Financing · 2026-06-25 [Nuvation Bio proposes $200.0 million convertible notes offering](https://aibio.space/news/nuvation-bio-proposes-200-0-million-convertible-notes-offering/) Nuvation Bio plans $200.0 million of notes due 2032 and expects to use the proceeds to repay its senior secured loan and pay for capped calls. The rate and conversion price are not set until pricing. [NUVB](https://aibio.space/companies/nuvation-bio/)
145. Debt Financing · 2026-06-25 [Ligand Pharmaceuticals completes $700.0 million 0.00% convertible senior notes offering](https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/) Ligand closed $700.0 million of 0.00% convertible senior notes due 2031 after the initial purchasers exercised their option in full. Net proceeds were approximately $678.2 million, with about $72.9 million going to note hedges and approximately $60 million to a share repurchase. The initial conversion price is approximately $334.27 per share. [LGND](https://aibio.space/companies/ligand-pharmaceuticals/)
146. Debt Financing · 2026-06-24 [4D Molecular Therapeutics signs up to $200.0 million Hercules loan](https://aibio.space/news/4d-molecular-therapeutics-signs-up-200-0-million-hercules-loan/) Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds. [FDMT](https://aibio.space/companies/4d-molecular-therapeutics/)
147. Debt Financing · 2026-06-23 [Sangamo files Chapter 11 with DIP financing from Northridge ATM](https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/) Sangamo filed for Chapter 11 in Delaware on June 23, 2026 and seeks court approval of DIP financing from Northridge ATM, LLC. Eli Lilly and Astellas have signed stalking horse bids for its assets. [SGMOQ](https://aibio.space/companies/sangamo-therapeutics/)
148. Debt Financing · 2026-06-23 [CalciMedica pushes Avenue loan maturity to 2029 and cuts warrant price](https://aibio.space/news/calcimedica-pushes-avenue-loan-maturity-2029-cuts-warrant-price/) Avenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00. [CALC](https://aibio.space/companies/calcimedica/)
149. Debt Financing · 2026-06-23 [CERo Therapeutics amends $1,413,600 promissory note with SRX Health](https://aibio.space/news/cero-therapeutics-amends-1-413-600-promissory-note-srx-health/) CERo Therapeutics amended a note with SRX Health Solutions, Inc. that converts into common stock at a price set by recent trading. The maximum is $1,413,600, of which $663,600 was funded on June 23, 2026. [CERO](https://aibio.space/companies/cero-therapeutics/)
150. Debt Financing · 2026-06-22 [Ligand plans $550 million of convertible notes due 2031](https://aibio.space/news/ligand-plans-550-million-convertible-notes-due-2031/) Ligand plans a private offering of $550.0 million of notes due 2031 to fund note hedges, a repurchase of up to $75 million of stock and general purposes, including a pending deal for Xoma Royalty Corporation. [LGND](https://aibio.space/companies/ligand-pharmaceuticals/)
151. Debt Financing · 2026-06-22 [Aditxt adds $769,230.77 in senior secured convertible notes](https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/) Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors. [ADTX](https://aibio.space/companies/aditxt/)
152. Debt Financing · 2026-06-22 [BetterLife closes CAD $2,000,000 convertible debenture financing](https://aibio.space/news/betterlife-closes-cad-2-000-000-convertible-debenture-financing/) BetterLife Pharma closed a CAD $2,000,000 convertible debenture on June 22, 2026, and a director and insider subscribed for the full amount. The conversion price compares with $0.07 per unit in an April 2026 private placement. [BETR](https://aibio.space/companies/betterlife-pharma/)
153. Debt Financing · 2026-06-22 [NeoGenomics completes $316.25 million convertible notes offering](https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/) NeoGenomics completed $316.25 million of 0.75% convertible senior notes due 2032 under an indenture with U.S. Bank Trust Company, National Association, as trustee. It used about $28.7 million of the proceeds on capped calls. [NEO](https://aibio.space/companies/neogenomics/)
154. Debt Financing · 2026-06-18 [PTC Therapeutics closes $550,000,000 convertible notes offering](https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/) PTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share. [PTCT](https://aibio.space/companies/ptc-therapeutics/)
155. Debt Financing · 2026-06-18 [Viatris completes €650,000,000 public offering of 4.250% senior notes due 2033](https://aibio.space/news/viatris-completes-650-000-000-public-offering-4-250-percent-senior/) Viatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter. [VTRS](https://aibio.space/companies/viatris/)
156. Debt Financing · 2026-06-17 [Jaguar Health amends Streeterville and Uptown royalty deals and extends a note to October](https://aibio.space/news/jaguar-health-amends-streeterville-uptown-royalty-deals-extends-note/) Jaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares. [JAGX](https://aibio.space/companies/jaguar-health/)
157. Debt Financing · 2026-06-17 [Adaptive Biotechnologies prices upsized $300 million convertible notes](https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/) Adaptive Biotechnologies priced $300 million of 0% convertible senior notes due 2031, upsized from $250 million. J. Wood Capital Advisors LLC, its financial advisor on the offering, agreed to purchase about $10 million of shares. [ADPT](https://aibio.space/companies/adaptive-biotechnologies/)
158. Debt Financing · 2026-06-17 [Omeros agrees to repurchase up to $16.0 million of convertible notes](https://aibio.space/news/omeros-agrees-repurchase-up-16-0-million-convertible-notes/) Omeros agreed to repurchase up to about $16.0 million of 9.50% convertible notes due 2029 for a total of up to about $34.0 million. The final price depends on the stock's trading in an averaging period that began June 18, 2026. [OMER](https://aibio.space/companies/omeros/)
159. Debt Financing · 2026-06-17 [Gossamer Bio completes exchange of 2027 convertible notes into secured notes](https://aibio.space/news/gossamer-bio-completes-exchange-2027-convertible-notes-secured-notes/) Gossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt. [GOSS](https://aibio.space/companies/gossamer-bio/)
160. Debt Financing · 2026-06-16 [Dyne Therapeutics draws $50.0 million more under Hercules facility](https://aibio.space/news/dyne-therapeutics-draws-50-0-million-more-under-hercules-facility/) Dyne Therapeutics' Hercules facility now totals up to $400.0 million, with $200.0 million outstanding after a $50.0 million draw on June 16, 2026. Hercules Capital, Inc. is administrative agent and collateral agent for the lenders. [DYN](https://aibio.space/companies/dyne-therapeutics/)
161. Debt Financing · 2026-06-15 [PDS Biotechnology closes $6,000,000 note with YA II PN](https://aibio.space/news/pds-biotechnology-closes-6-000-000-note-ya-ii-pn/) PDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program. [PDSB](https://aibio.space/companies/pds-biotechnology/)
162. Debt Financing · 2026-06-15 [Adaptive Biotechnologies plans $250 million of convertible notes](https://aibio.space/news/adaptive-biotechnologies-plans-250-million-convertible-notes/) Adaptive Biotechnologies plans a $250 million offering of convertible senior notes due 2031 and expects to use up to $25 million of the proceeds to repurchase common stock. The interest rate and conversion terms will be set only at pricing. [ADPT](https://aibio.space/companies/adaptive-biotechnologies/)
163. Debt Financing · 2026-06-12 [Viatris offers €650,000,000 of 4.250% senior notes due 2033](https://aibio.space/news/viatris-offers-650-000-000-4-250-percent-senior-notes-due-2033/) Viatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion. [VTRS](https://aibio.space/companies/viatris/)
164. Debt Financing · 2026-06-12 [Clearmind sells $1,000,000 of convertible notes at 90% of principal](https://aibio.space/news/clearmind-sells-1-000-000-convertible-notes-90-percent-principal/) Clearmind Medicine will issue $1,000,000 of convertible notes for $900,000 in cash, under a one-time exception to its own $2,500,000 quarterly limit. The agreement also amends the conversion price and sets a $1.875 floor price per share. [CMND](https://aibio.space/companies/clearmind-medicine/)
165. Debt Financing · 2026-06-11 [IQVIA issues €950,000,000 of 4.625% senior notes due 2033](https://aibio.space/news/iqvia-issues-950-000-000-4-625-percent-senior-notes-due-2033/) IQVIA's €950,000,000 of 4.625% senior notes due 2033 are governed by a June 11, 2026 indenture with U.S. Bank Trust Company, National Association as trustee. Its 2025 net income of $1.36 billion was slightly below 2024. [IQV](https://aibio.space/companies/iqvia/)
166. Debt Financing · 2026-06-11 [CDT Equity repays legacy notes and signs $1,460,000 JJ Astor loan](https://aibio.space/news/cdt-equity-repays-legacy-notes-signs-1-460-000-jj-astor-loan/) CDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million. [CDT](https://aibio.space/companies/cdt-equity/)
167. Debt Financing · 2026-06-11 [Xeris exchanges $23 million of 2028 convertible notes for cash and stock](https://aibio.space/news/xeris-exchanges-23-million-2028-convertible-notes-cash-stock/) Xeris will retire about $23 million of its 8.00% convertible notes due 2028 for about $23 million in cash plus common stock, with Morgan Stanley as placement agent. About $10.5 million of the notes will remain outstanding. [XERS](https://aibio.space/companies/xeris-biopharma/)
168. Debt Financing · 2026-06-10 [BioRestorative sets up $1,000,000 revolving loan from Bowery Group](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/) BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million. [BRTX](https://aibio.space/companies/biorestorative-therapies/)[NUWE](https://aibio.space/companies/nuwellis/)[ISPC](https://aibio.space/companies/ispecimen/)
169. Debt Financing · 2026-06-10 [Precision BioSciences extends Banc of California term loan](https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/) Precision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents. [DTIL](https://aibio.space/companies/precision-biosciences/)
170. Debt Financing · 2026-06-09 [Idorsia takes up to CHF 250 million senior secured term loan](https://aibio.space/news/idorsia-takes-up-chf-250-million-senior-secured-term-loan/) The first CHF 150 million tranche will refinance the existing New Money Facility, of which CHF 105 million has been drawn. [IDIA](https://aibio.space/companies/idorsia/)
171. Debt Financing · 2026-06-08 [Vivos Therapeutics issues convertible note of up to $5,000,000](https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/) Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed. [VVOS](https://aibio.space/companies/vivos-therapeutics/)
172. Debt Financing · 2026-06-08 [Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan](https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/) Celcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day. [CELC](https://aibio.space/companies/celcuity/)
173. Debt Financing · 2026-06-05 [IGC Pharma extends $12,000,000 bank credit facility with O-Bank](https://aibio.space/news/igc-pharma-extends-12-000-000-bank-credit-facility-o-bank/) IGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate. [IGC](https://aibio.space/companies/igc-pharma/)
174. Debt Financing · 2026-06-05 [Cerus takes up to $65.0 million secured term loan from MidCap](https://aibio.space/news/cerus-takes-up-65-0-million-secured-term-loan-midcap/) Cerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%. [CERS](https://aibio.space/companies/cerus/)
175. Debt Financing · 2026-06-05 [Inotiv enters $65.5 million DIP credit agreement after Chapter 11 filing](https://aibio.space/news/inotiv-enters-65-5-million-dip-credit-agreement-after-chapter-11/) Inotiv's $65.5 million debtor-in-possession facility includes $25,000,000 of new money and rolls up $40,521,753.47 of prepetition bridge loans into superpriority term loans. Both tranches pay interest in kind at Adjusted Term SOFR plus 11.5%.
176. Debt Financing · 2026-06-04 [IMUNON to raise $10 million through preferred stock and secured notes](https://aibio.space/news/imunon-raise-10-million-through-preferred-stock-secured-notes/) IMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025. [IMNN](https://aibio.space/companies/imunon/)
177. Debt Financing · 2026-06-04 [Luye Pharma to issue US$180,000,000 bonds due 2031](https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/) Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete. [2186](https://aibio.space/companies/luye-pharma/)
178. Debt Financing · 2026-06-04 [Syndax agrees to $250.0 million private placement of 2.25% convertible notes](https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/) Syndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million. [SNDX](https://aibio.space/companies/syndax-pharmaceuticals/)
179. Debt Financing · 2026-06-04 [Syndax agrees to sell $250.0 million of 2.25% convertible notes due 2031](https://aibio.space/news/syndax-agrees-sell-250-0-million-2-25-percent-convertible-notes-due/) Syndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share. [SNDX](https://aibio.space/companies/syndax-pharmaceuticals/)
180. Debt Financing · 2026-06-03 [CONMED agrees to buy back 2.250% convertible notes due 2027 for cash](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/) CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show. [CNMD](https://aibio.space/companies/conmed/)
181. Debt Financing · 2026-06-03 [FONAR closes merger with $20 million term loan and $15 million revolver](https://aibio.space/news/fonar-closes-merger-20-million-term-loan-15-million-revolver/) FONAR's merger closed on June 3, 2026, and the company is now a wholly owned subsidiary of FONAR, LLC. As a borrower and guarantor under a new OceanFirst Bank credit agreement, it is bound by a $20 million term loan facility and a $15 million revolving facility secured by substantially all assets.
182. Debt Financing · 2026-06-03 [Aditxt issues senior secured convertible notes with 35% discount](https://aibio.space/news/aditxt-issues-senior-secured-convertible-notes-35-percent-discount/) Aditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026. [ADTX](https://aibio.space/companies/aditxt/)
183. Debt Financing · 2026-06-03 [Gossamer Bio exchanges $181,052,000 of 2027 convertible notes](https://aibio.space/news/gossamer-bio-exchanges-181-052-000-2027-convertible-notes/) Gossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture. [GOSS](https://aibio.space/companies/gossamer-bio/)
184. Debt Financing · 2026-06-03 [Celcuity prices upsized $500,000,000 convertible notes offering](https://aibio.space/news/celcuity-prices-upsized-500-000-000-convertible-notes-offering/) Celcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan. [CELC](https://aibio.space/companies/celcuity/)
185. Debt Financing · 2026-06-03 [Helix BioPharma closes C$3,673,000 convertible debenture placement](https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/) The unsecured debentures carry 25.00% simple interest, mature 14 months after closing and can convert at C$1.42 per share. [HBP](https://aibio.space/companies/helix-biopharma/)
186. Debt Financing · 2026-06-03 [Celcuity proposes $400,000,000 convertible notes, then prices $500,000,000 at 0.250%](https://aibio.space/news/celcuity-proposes-400-000-000-convertible-notes-then-prices-500-000/) The notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42. [CELC](https://aibio.space/companies/celcuity/)
187. Debt Financing · 2026-06-02 [Inotiv plans $326 million debt cut through prepackaged Chapter 11](https://aibio.space/news/inotiv-plans-326-million-debt-cut-through-prepackaged-chapter-11/) Inotiv's prepackaged Chapter 11 plan would cut about $326 million of funded debt, convert a substantial portion of it into equity and cancel existing equity interests.
188. Debt Financing · 2026-06-02 [Mineralys signs up to $500.0 million senior secured term loan](https://aibio.space/news/mineralys-signs-up-500-0-million-senior-secured-term-loan/) Mineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment. [MLYS](https://aibio.space/companies/mineralys-therapeutics/)
189. Debt Financing · 2026-06-02 [Sensus Healthcare signs $15,000,000 revolving note with City National Bank of Florida](https://aibio.space/news/sensus-healthcare-signs-15-000-000-revolving-note-city-national-bank/) City National Bank of Florida will lend up to $15,000,000 under a revolving note that matures June 5, 2027. [SRTS](https://aibio.space/companies/sensus-healthcare/)
190. Debt Financing · 2026-06-02 [Maravai LifeSciences signs $150.0 million term loan and $30.0 million revolver](https://aibio.space/news/maravai-lifesciences-signs-150-0-million-term-loan-30-0-million/) A new credit agreement refinances a 2020 facility, with BSP Agency, LLC as administrative and collateral agent. [MRVI](https://aibio.space/companies/maravai-lifesciences/)
191. Debt Financing · 2026-06-01 [Teleflex prices $500.0 million of 5.875% senior notes due 2032](https://aibio.space/news/teleflex-prices-500-0-million-5-875-percent-senior-notes-due-2032/) Teleflex will use the proceeds, with cash on hand, to redeem its outstanding 4.625% Senior Notes due 2027. The notes are being sold in a private offering. [TFX](https://aibio.space/companies/teleflex/)
192. Debt Financing · 2026-06-01 [Clearmind to issue $1,500,000 in convertible promissory notes](https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/) The notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026. [CMND](https://aibio.space/companies/clearmind-medicine/)
193. Debt Financing · 2026-06-01 [Nutriband extends $5 million related-party credit line tied to Kindeva work](https://aibio.space/news/nutriband-extends-5-million-related-party-credit-line-tied-kindeva/) Nutriband amended its $5 million credit line with TII Jet Services, a lender in Portugal. Advances carry 7% interest and may be used only for work with Kindeva toward the fentanyl NDA. [NTRB](https://aibio.space/companies/nutriband/)
194. Debt Financing · 2026-05-29 [Nuo Therapeutics closes $675,000 interim loan at 12% interest](https://aibio.space/news/nuo-therapeutics-closes-675-000-interim-loan-12-percent-interest/) Five lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028. [AURX](https://aibio.space/companies/nuo-therapeutics/)
195. Debt Financing · 2026-05-29 [China Resources Pharmaceutical plans RMB5 billion medium term notes](https://aibio.space/news/china-resources-pharmaceutical-plans-rmb5-billion-medium-term-notes/) A wholly owned subsidiary received registration for up to RMB5 billion of medium term notes, valid for two years, with no issue announced yet. [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
196. Debt Financing · 2026-05-28 [Medline sells $1,250.0 million and $750.0 million in senior secured notes](https://aibio.space/news/medline-sells-1-250-0-million-750-0-million-senior-secured-notes/) Medline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets. [MDLN](https://aibio.space/companies/medline/)
197. Debt Financing · 2026-05-28 [CERo Therapeutics issues $937,500 convertible note to SRX Health Solutions](https://aibio.space/news/cero-therapeutics-issues-937-500-convertible-note-srx-health-solutions/) The note was sold for $750,000 and bears 10% interest, with conversion at the lesser of $0.05 or a discount to recent trading prices. [CERO](https://aibio.space/companies/cero-therapeutics/)
198. Debt Financing · 2026-05-28 [Royalty Pharma signs new $1.8 billion revolving credit facility maturing in 2031](https://aibio.space/news/royalty-pharma-signs-new-1-8-billion-revolving-credit-facility/) Royalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K. [RPRX](https://aibio.space/companies/royalty-pharma/)
199. Debt Financing · 2026-05-27 [Medicus Pharma closes secured notes with Streeterville Capital](https://aibio.space/news/medicus-pharma-closes-secured-notes-streeterville-capital/) The lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases. [MDCX](https://aibio.space/companies/medicus-pharma/)
200. Debt Financing · 2026-05-27 [Teleflex enters new credit agreement with JPMorgan Chase as agent](https://aibio.space/news/teleflex-enters-new-credit-agreement-jpmorgan-chase-agent/) The credit agreement names JPMorgan Chase Bank, N.A. as administrative agent. The company's Form 8-K describes a revolver and two term loan facilities that refinance its earlier agreement. [TFX](https://aibio.space/companies/teleflex/)
201. Debt Financing · 2026-05-27 [CONMED amends JPMorgan credit agreement to add a delayed draw term loan](https://aibio.space/news/conmed-amends-jpmorgan-credit-agreement-add-delayed-draw-term-loan/) The first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent. [CNMD](https://aibio.space/companies/conmed/)
202. Debt Financing · 2026-05-27 [Biophytis changes Hexagon bond facility to make it revolving](https://aibio.space/news/biophytis-changes-hexagon-bond-facility-make-revolving/) Biophytis amended its straight bond financing with Hexagon Capital Fund a second time, making the facility revolving and reducing its cost. [ALBPS](https://aibio.space/companies/biophytis/)
203. Debt Financing · 2026-05-26 [TuHURA takes first $1,700,000 draw on Parkview revolving credit facility](https://aibio.space/news/tuhura-takes-first-1-700-000-draw-parkview-revolving-credit-facility/) The $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes. [HURA](https://aibio.space/companies/tuhura-biosciences/)
204. Debt Financing · 2026-05-26 [Cartesian Therapeutics signs term loan of up to $150.0 million with K2 HealthVentures](https://aibio.space/news/cartesian-therapeutics-signs-term-loan-up-150-0-million-k2/) Cartesian drew $50.0 million at closing under a senior secured loan that can reach $150.0 million, with the lenders able to convert up to $15.0 million into common stock at $8.2526 a share. The loan carries a minimum cash covenant starting April 1, 2027, and the 8-K does not name the individual lenders. [RNAC](https://aibio.space/companies/cartesian-therapeutics/)
205. Debt Financing · 2026-05-22 [Cartesian Therapeutics signs up to $150.0 million senior secured term loans](https://aibio.space/news/cartesian-therapeutics-signs-up-150-0-million-senior-secured-term/) The loans carry a variable rate of at least 8.95% and mature on June 1, 2030. Only the first $50.0 million was funded at closing, and the two later tranches depend on milestones. [RNAC](https://aibio.space/companies/cartesian-therapeutics/)
206. Debt Financing · 2026-05-20 [Senti Biosciences issues $10.0 million senior secured convertible notes](https://aibio.space/news/senti-biosciences-issues-10-0-million-senior-secured-convertible-notes/) Celadon Partners SPV 24 bought the notes, and Acquiom Agency Services LLC was named collateral agent. [SNTI](https://aibio.space/companies/senti-biosciences/)
207. Debt Financing · 2026-05-19 [AIM ImmunoTech pushes Streeterville note maturity to June 2027](https://aibio.space/news/aim-immunotech-pushes-streeterville-note-maturity-june-2027/) The note is now due June 30, 2027. The balance is about $1.68 million after the amendment and the extension fee. [AIM](https://aibio.space/companies/aim-immunotech/)
208. Debt Financing · 2026-05-18 [Assertio's $23.50 cash merger would give 2027 convertible noteholders repurchase rights](https://aibio.space/news/assertios-23-50-cash-merger-would-give-2027-convertible-noteholders/) The merger with Zydus Worldwide DMCC would let noteholders require repurchase at 100% of principal plus accrued interest. Parent waived the requirement that Assertio launch a note offer.
209. Debt Financing · 2026-05-18 [Gossamer Bio launches exchange offer for 5.00% convertible notes](https://aibio.space/news/gossamer-bio-launches-exchange-offer-5-00-percent-convertible-notes/) The offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants. [GOSS](https://aibio.space/companies/gossamer-bio/)
210. Debt Financing · 2026-05-15 [WuXi AppTec agrees to issue RMB6,780 million convertible bonds](https://aibio.space/news/wuxi-apptec-agrees-issue-rmb6-780-million-convertible-bonds/) WuXi AppTec signed a subscription agreement on May 14, 2026 for bonds with an initial conversion price of HK$153.00 per H share. [603259](https://aibio.space/companies/wuxi-apptec/)
211. Debt Financing · 2026-05-14 [Ocugen closes $130.0 million of 6.75% convertible notes](https://aibio.space/news/ocugen-closes-130-0-million-6-75-percent-convertible-notes/) The notes include the full exercise of a $15.0 million over-allotment option. Ocugen used approximately $32.7 million of the proceeds to repay its Avenue loan. [OCGN](https://aibio.space/companies/ocugen/)
212. Debt Financing · 2026-05-14 [Inotiv amends credit agreement with $40.0 million bridge facility](https://aibio.space/news/inotiv-amends-credit-agreement-40-0-million-bridge-facility/) Inotiv borrowed $27.5 million under the bridge facility and used it to repay its revolving loans, which were then terminated. The amendment also excludes some covenant tests and adds strategic alternatives milestones.
213. Debt Financing · 2026-05-14 [Gilead sells senior notes due 2028 through 2034 in public offering](https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/) Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters. [GILD](https://aibio.space/companies/gilead-sciences/)
214. Debt Financing · 2026-05-14 [Senti Biosciences signs up to $40 million in convertible note financing](https://aibio.space/news/senti-biosciences-signs-up-40-million-convertible-note-financing/) An affiliate of Celadon Partners SPV 24 may buy notes in two tranches. The first tranche is $10 million and is expected to close in May. [SNTI](https://aibio.space/companies/senti-biosciences/)
215. Debt Financing · 2026-05-13 [Spruce Biosciences details its $50.0 million Avenue Capital loan facility](https://aibio.space/news/spruce-biosciences-details-50-0-million-avenue-capital-loan-facility/) Avenue Capital Management II, L.P. is the lender under a term loan facility signed January 7, 2026. The first $15.0 million tranche funded after closing. [SPRB](https://aibio.space/companies/spruce-biosciences/)
216. Debt Financing · 2026-05-13 [BiomX sets up $2,000,000 credit line from Mandragola with 12% notes](https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/) Mandragola Ltd is the lender under a credit line that issues 12% convertible promissory notes for each advance. Mandragola also received a five-year warrant.
217. Debt Financing · 2026-05-13 [Armata Pharmaceuticals takes $25 million secured loan from Innoviva](https://aibio.space/news/armata-pharmaceuticals-takes-25-million-secured-loan-innoviva/) The 14.0% term loan matures in January 2029 and is secured by substantially all of the company's assets. The lender is a subsidiary of Innoviva, which the filing describes as a principal shareholder. [ARMP](https://aibio.space/companies/armata-pharmaceuticals/)
218. Debt Financing · 2026-05-13 [Armata Pharmaceuticals signs $25 million secured loan with Innoviva at 14.0%](https://aibio.space/news/armata-pharmaceuticals-signs-25-million-secured-loan-innoviva-14-0/) The term loan from Innoviva Strategic Opportunities LLC matures January 11, 2029 and is secured by substantially all company assets. Armata reported about $4.8 million of unrestricted cash and cash equivalents at March 31, 2026. [ARMP](https://aibio.space/companies/armata-pharmaceuticals/)
219. Debt Financing · 2026-05-12 [Mirum prices $600 million of 0% convertible notes and refinances 2029 debt](https://aibio.space/news/mirum-prices-600-million-0-percent-convertible-notes-refinances-2029/) The notes carry no interest and convert at about $138.94 a share, a 30% premium to the May 12 price. Mirum swapped $237.2 million of 4% notes due 2029 for cash and shares. [MIRM](https://aibio.space/companies/mirum-pharmaceuticals/)
220. Debt Financing · 2026-05-12 [Mirum proposes $600.0 million convertible notes offering](https://aibio.space/news/mirum-proposes-600-0-million-convertible-notes-offering/) Mirum plans to sell $600.0 million of convertible senior notes due 2032, with an option for up to $90.0 million more. Part of the proceeds would go toward exchanges of its 2029 notes. [MIRM](https://aibio.space/companies/mirum-pharmaceuticals/)
221. Debt Financing · 2026-05-12 [Aquestive enters $150 million debt facility with Oaktree](https://aibio.space/news/aquestive-enters-150-million-debt-facility-oaktree/) The facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones. [AQST](https://aibio.space/companies/aquestive-therapeutics/)
222. Debt Financing · 2026-05-12 [FOXO exchanges Series A preferred for senior unsecured notes](https://aibio.space/news/foxo-exchanges-series-preferred-senior-unsecured-notes/) Two institutional holders swapped Series A preferred stock for non-convertible notes of $5,307,096.94 and $2,467,988.34, due May 12, 2027. [FOXO](https://aibio.space/companies/foxo-technologies/)
223. Debt Financing · 2026-05-12 [Tempus AI completes $460.0 million convertible notes offering](https://aibio.space/news/tempus-ai-completes-460-0-million-convertible-notes-offering/) The notes carry no regular interest and mature May 15, 2032, after the initial purchasers exercised their option in full. [TEM](https://aibio.space/companies/tempus-ai/)
224. Debt Financing · 2026-05-11 [Travere sells $525 million of 2032 convertible notes to buy back $221 million of 2029 notes](https://aibio.space/news/travere-sells-525-million-2032-convertible-notes-buy-back-221-million/) The 0.50% notes would lift convertible principal to $619.9 million but cut the coupon. Travere said it would spend about $350.9 million to repurchase part of the older debt. [TVTX](https://aibio.space/companies/travere-therapeutics/)
225. Debt Financing · 2026-05-11 [NexGel issues $1,000,000 convertible note to new director Brian J. Kieser](https://aibio.space/news/nexgel-issues-1-000-000-convertible-note-new-director-brian-j-kieser/) The unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing. [NXGL](https://aibio.space/companies/nexgel/)
226. Debt Financing · 2026-05-08 [Lifeloc borrows $500,000 from its Chairman and CFO](https://aibio.space/news/lifeloc-borrows-500-000-chairman-cfo/) Lifeloc Technologies entered into a $500,000 promissory note with Vern Kornelsen, its Chief Financial Officer and Chairman of the Board. The note carries 10.5% interest and is secured by its Wheat Ridge office and most of its assets. [LCTC](https://aibio.space/companies/lifeloc-technologies/)
227. Debt Financing · 2026-05-07 [Gelteq agrees to up to $3.5 million in convertible note financing](https://aibio.space/news/gelteq-agrees-up-3-5-million-convertible-note-financing/) An institutional investor will fund up to $3.5 million in two tranches. The first note carries 7% interest, matures in eighteen months and converts at a price that cannot fall below $0.50. [GELS](https://aibio.space/companies/gelteq/)
228. Debt Financing · 2026-05-06 [Viridian completes $250,000,000 convertible notes offering](https://aibio.space/news/viridian-completes-250-000-000-convertible-notes-offering/) Viridian's $250,000,000 offering of 1.75% convertible senior notes due 2032 includes the full $25.0 million over-allotment option. A concurrent sale of 7,352,942 shares was priced at $17.00 a share. [VRDN](https://aibio.space/companies/viridian-therapeutics/)
229. Debt Financing · 2026-05-06 [Citius Oncology prices $11.5 million warrant inducement and signs Avenue term loan](https://aibio.space/news/citius-oncology-prices-11-5-million-warrant-inducement-signs-avenue/) Citius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count. [CTOR](https://aibio.space/companies/citius-oncology/)
230. Debt Financing · 2026-05-06 [Citius Oncology announces up to $36.5 million in loan and warrant financing](https://aibio.space/news/citius-oncology-announces-up-36-5-million-loan-warrant-financing/) Citius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares. [CTOR](https://aibio.space/companies/citius-oncology/)
231. Debt Financing · 2026-05-05 [Ocugen plans $115 million convertible senior notes offering](https://aibio.space/news/ocugen-plans-115-million-convertible-senior-notes-offering/) Ocugen plans $115 million of 6.75% convertible senior notes due 2034, with an option that takes the total to $130 million. Proceeds include $32.7 million to retire Avenue debt at 12.5%. [OCGN](https://aibio.space/companies/ocugen/)
232. Debt Financing · 2026-05-05 [Travere proposes $400 million convertible notes offering](https://aibio.space/news/travere-proposes-400-million-convertible-notes-offering/) Travere plans to sell $400 million of convertible senior notes due 2032, with an option for up to $60 million more. It intends to use part of the proceeds to repurchase 2029 notes for cash. [TVTX](https://aibio.space/companies/travere-therapeutics/)
233. Debt Financing · 2026-05-04 [Lexicon signs up to $100 million loan with Hercules Capital](https://aibio.space/news/lexicon-signs-up-100-million-loan-hercules-capital/) Lexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share. [LXRX](https://aibio.space/companies/lexicon-pharmaceuticals/)
234. Debt Financing · 2026-05-01 [CERo sells convertible note with $500,000 face value to Keystone](https://aibio.space/news/cero-sells-convertible-note-500-000-face-value-keystone/) CERo Therapeutics Holdings issued a convertible promissory note to Keystone Capital Partners, LLC on April 27, 2026, with a purchase price of $400,000 and a principal face value of $500,000. [CERO](https://aibio.space/companies/cero-therapeutics/)
235. Debt Financing · 2026-05-01 [Alphatec signs $175.0 million term loan and $125.0 million revolver](https://aibio.space/news/alphatec-signs-175-0-million-term-loan-125-0-million-revolver/) JPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements. [ATEC](https://aibio.space/companies/alphatec/)
236. Debt Financing · 2026-04-30 [PDS Biotechnology agrees to sell $6,000,000 promissory note](https://aibio.space/news/pds-biotechnology-agrees-sell-6-000-000-promissory-note/) The 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share. [PDSB](https://aibio.space/companies/pds-biotechnology/)
237. Debt Financing · 2026-04-30 [Clearmind amends convertible note deal, leaving $10 million available](https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/) The amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes. [CMND](https://aibio.space/companies/clearmind-medicine/)
238. Debt Financing · 2026-04-27 [Scienture closes $8 million note purchase with Streeterville Capital](https://aibio.space/news/scienture-closes-8-million-note-purchase-streeterville-capital/) The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent. [SCNX](https://aibio.space/companies/scienture/)
239. Debt Financing · 2026-04-20 [IGC Pharma sells promissory notes to FirstFire and Vanquish Funding for $307,000 and $207,000](https://aibio.space/news/igc-pharma-sells-promissory-notes-firstfire-vanquish-funding-307-000/) The notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default. [IGC](https://aibio.space/companies/igc-pharma/)
240. Debt Financing · 2026-04-17 [Emergent BioSolutions closes $150 million term loan with OrbiMed, cuts ABL revolver to $50 million](https://aibio.space/news/emergent-biosolutions-closes-150-million-term-loan-orbimed-cuts-abl/) Emergent drew a $150 million term loan with OrbiMed as administrative agent and repaid its prior credit agreement. Interest is Term SOFR plus 6.25%, with a 3.00% floor, and the loan matures as late as April 16, 2031. The asset-based revolver falls from $100 million to $50 million. [EBS](https://aibio.space/companies/emergent-biosolutions/)
241. Debt Financing · 2026-04-17 [Emergent BioSolutions draws $150 million OrbiMed term loan, repays prior credit agreement](https://aibio.space/news/emergent-biosolutions-draws-150-million-orbimed-term-loan-repays-prior/) The Credit Agreement also provides a $75 million delayed draw term loan, available for 24 months. Interest is Term SOFR plus 6.25% per annum, with a 3.00% floor. [EBS](https://aibio.space/companies/emergent-biosolutions/)
242. Debt Financing · 2026-04-02 [Caris Life Sciences takes $400,000,000 term loan from Blue Owl and Blackstone funds](https://aibio.space/news/caris-life-sciences-takes-400-000-000-term-loan-blue-owl-blackstone/) Caris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025. [CAI](https://aibio.space/companies/caris-life-sciences/)
243. Debt Financing · 2026-04-01 [Apollomics signs $2.0 million convertible note with its chairman and CEO](https://aibio.space/news/apollomics-signs-2-0-million-convertible-note-chairman-ceo/) Apollomics signed a $2.0 million unsecured note with its chairman and chief executive, Hung-Wen (Howard) Chen, on March 30, 2026, at 0% interest, which converts into equity at a 20% discount if the company later raises at least $10.0 million. [APLM](https://aibio.space/companies/apollomics/)
244. Debt Financing · 2026-03-31 [Zenas BioPharma closes $200,000,000 convertible senior notes offering due 2032](https://aibio.space/news/zenas-biopharma-closes-200-000-000-convertible-senior-notes-offering/) Zenas BioPharma closed a $200 million offering of 2.50% convertible senior notes due 2032, with net proceeds of about $193.7 million and Jefferies, Evercore, Citigroup and Guggenheim as representatives. Its 10-K reports substantial doubt about going concern. [ZBIO](https://aibio.space/companies/zenas-biopharma/)
245. Debt Financing · 2026-03-24 [CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%](https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/) CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%. [CYDY](https://aibio.space/companies/cytodyn/)
246. Debt Financing · 2026-03-23 [Turn Therapeutics draws $7 million from $25 million secured loan with Avenue](https://aibio.space/news/turn-therapeutics-draws-7-million-25-million-secured-loan-avenue/) Turn Therapeutics signed a term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. It bears interest of at least 12.25%, is secured on the company's assets, and only $7.0 million is committed up front. [TTRX](https://aibio.space/companies/turn-therapeutics/)
247. Debt Financing · 2026-02-23 [MoonLake amends Hercules loan, draws $25.0 million and keeps up to $400.0 million in later tranches](https://aibio.space/news/moonlake-amends-hercules-loan-draws-25-0-million-keeps-up-400-0/) MoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported. [MLTX](https://aibio.space/companies/moonlake-immunotherapeutics/)
248. Debt Financing · 2026-02-04 [Maze Therapeutics draws $40.0 million under Hercules term loan facility of up to $200.0 million](https://aibio.space/news/maze-therapeutics-draws-40-0-million-under-hercules-term-loan-facility/) Maze received an initial $40.0 million term loan and says net proceeds were approximately $38.4 million. Up to $160.0 million more is available if conditions are met. It also ended its Banc of California loan. [MAZE](https://aibio.space/companies/maze-therapeutics/)
249. Debt Financing · 2026-02-03 [Replimune amends Hercules loan, draws $35 million and delays repayment to October 2027](https://aibio.space/news/replimune-amends-hercules-loan-draws-35-million-delays-repayment/) The Third Amendment raises the third tranche to $35 million, which was funded at closing, and sets the interest rate at the greater of 8.50% or Prime plus 1.75%. Replimune says its cash runway now reaches late into the first quarter of 2027. [REPL](https://aibio.space/companies/replimune/)
250. Debt Financing · 2026-02-03 [Amneal cuts term loan margin by 50 basis points, estimates $11 million annual interest savings](https://aibio.space/news/amneal-cuts-term-loan-margin-50-basis-points-estimates-11-million/) Amneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032. [AMRX](https://aibio.space/companies/amneal-pharmaceuticals/)
251. Debt Financing · 2026-01-27 [Savara amends Hercules loan agreement, resets draw terms on up to $75 million of added term loans](https://aibio.space/news/savara-amends-hercules-loan-agreement-resets-draw-terms-up-75-million/) As amended, the loan agreement provides for up to $105 million of term loans, and the added draws depend on FDA approval of MOLBREEVI for aPAP. Two covenant compliance dates move to April 1, 2027 and September 30, 2027. [SVRA](https://aibio.space/companies/savara/)
252. Debt Financing · 2026-01-21 [enGene Holdings (now enGene Therapeutics) expands Hercules loan to up to $125 million](https://aibio.space/news/engene-holdings-now-engene-therapeutics-expands-hercules-loan-up-125/) The Second Amendment draws $25 million at closing to refinance existing term loans. Further tranches depend on milestones. [ENGN](https://aibio.space/companies/engene-therapeutics/)
253. Debt Financing · 2026-01-15 [BridgeBio prices $550 million of 0.75% convertible notes to refinance 2027 debt](https://aibio.space/news/bridgebio-prices-550-million-0-75-percent-convertible-notes-refinance/) The notes due 2033 carry a 45% conversion premium. Underwriters later took the full option, and BridgeBio bought back about 1.1 million shares alongside the sale. [BBIO](https://aibio.space/companies/bridgebio-pharma/)
254. Debt Financing · 2026-01-15 [Cell Source closes $1.875 million convertible note placement and plans Nasdaq uplist](https://aibio.space/news/cell-source-closes-1-875-million-convertible-note-placement-plans/) Cell Source closed $1,875,000 of original issue discount convertible notes for $1,500,000 in gross proceeds. The notes convert at 90% of a recent low price, and buyers also received warrants at $.40. [CLCS](https://aibio.space/companies/cell-source/)
255. Debt Financing · 2026-01-07 [Arrowhead Pharmaceuticals prices $625,000,000 of 0.00% convertible notes due 2032](https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/) Arrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing. [ARWR](https://aibio.space/companies/arrowhead-pharmaceuticals/)
256. Debt Financing · 2026-01-02 [Bausch + Lomb closes $2,802,125,000 term loan refinancing](https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/) Bausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash. [BLCO](https://aibio.space/companies/bausch-lomb/)
257. Debt Financing · 2025-12-30 [Collegium closes $980 million syndicated credit facility with Truist Bank as agent](https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-truist-bank/) The five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size. [COLL](https://aibio.space/companies/collegium-pharmaceutical/)
258. Debt Financing · 2025-12-30 [Collegium closes $980 million syndicated credit facility, repays Pharmakon term loan](https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-repays/) The $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing. [COLL](https://aibio.space/companies/collegium-pharmaceutical/)
259. Debt Financing · 2025-12-08 [Dyne Therapeutics borrows $50.0 million second tranche under amended Hercules term loan](https://aibio.space/news/dyne-therapeutics-borrows-50-0-million-second-tranche-under-amended/) The First Amendment lets Dyne draw a $50.0 million tranche from Hercules Capital. Up to $75.0 million more depends on milestones, and the loan matures July 1, 2030 at prime plus 2.45% with a 7.50% floor. [DYN](https://aibio.space/companies/dyne-therapeutics/)
260. Debt Financing · 2025-11-26 [Mesoblast holders approve convertible notes and warrants for a director and Cova Holdings](https://aibio.space/news/mesoblast-holders-approve-convertible-notes-warrants-director-cova/) All resolutions passed by poll at the November 25, 2025 annual meeting. Shareholders also approved option grants and prior share issues. [MSB](https://aibio.space/companies/mesoblast/)
261. Debt Financing · 2025-11-24 [Cumberland Pharmaceuticals extends Pinnacle Bank credit line to October 2027](https://aibio.space/news/cumberland-pharmaceuticals-extends-pinnacle-bank-credit-line-october/) Cumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn. [CPIX](https://aibio.space/companies/cumberland-pharmaceuticals/)
262. Debt Financing · 2025-11-18 [Cogent Biosciences completes $230,000,000 offering of 1.625% convertible notes due 2031](https://aibio.space/news/cogent-biosciences-completes-230-000-000-offering-1-625-percent/) Cogent Biosciences closed a $230,000,000 offering of 1.625% convertible notes due 2031 on November 18, 2025, including the full over-allotment option. The 8-K names no underwriters, and the company's 2024 annual report showed operating cash use of $207.8 million that year. [COGT](https://aibio.space/companies/cogent-biosciences/)
263. Debt Financing · 2025-11-06 [Altimmune expands Hercules loan facility to $125 million and draws $20 million](https://aibio.space/news/altimmune-expands-hercules-loan-facility-125-million-draws-20-million/) The amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025. [ALT](https://aibio.space/companies/altimmune/)
264. Debt Financing · 2025-11-05 [Halozyme expands revolver to $750,000,000 and proposes two $650 million convertible note offerings](https://aibio.space/news/halozyme-expands-revolver-750-000-000-proposes-two-650-million/) Halozyme amended its credit agreement to raise the revolver to $750,000,000, with nothing drawn. It also proposed two $650 million convertible note offerings, with terms to be set at pricing. [HALO](https://aibio.space/companies/halozyme-therapeutics/)
265. Debt Financing · 2025-11-03 [Kyverna signs Oxford Finance loan facility of up to $150.0 million, expects to draw $25.0 million](https://aibio.space/news/kyverna-signs-oxford-finance-loan-facility-up-150-0-million-expects/) Kyverna signed a loan facility of up to $150.0 million with Oxford Finance and drew $25.0 million at closing, secured by substantially all of its assets. The company says its runway still runs into 2027, the same guidance it gave before the loan. [KYTX](https://aibio.space/companies/kyverna-therapeutics/)
266. Debt Financing · 2025-10-14 [Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million](https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/) Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. [CADL](https://aibio.space/companies/candel-therapeutics/)
267. Debt Financing · 2025-10-14 [Karyopharm closes recapitalization with 9.00% convertible notes and $12.5 million loan draw](https://aibio.space/news/karyopharm-closes-recapitalization-9-00-percent-convertible-notes-12-5/) Karyopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan. [KPTI](https://aibio.space/companies/karyopharm-therapeutics/)
268. Debt Financing · 2025-09-26 [Journey Medical extends SWK term loan maturity to June 2028 in credit agreement amendment](https://aibio.space/news/journey-medical-extends-swk-term-loan-maturity-june-2028-credit/) Journey Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025. [DERM](https://aibio.space/companies/journey-medical/)
269. Debt Financing · 2025-09-24 [uniQure amends Hercules term loan and draws $50 million to refinance debt](https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/) uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130. [QURE](https://aibio.space/companies/uniqure-n-v/)
270. Debt Financing · 2025-09-22 [Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031](https://aibio.space/news/cytokinetics-issues-750-0-million-1-75-percent-convertible-senior/) Cytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance. [CYTK](https://aibio.space/companies/cytokinetics/)
271. Debt Financing · 2025-09-18 [Medicus Pharma issues $8.0 million debenture to Yorkville fund](https://aibio.space/news/medicus-pharma-issues-8-0-million-debenture-yorkville-fund/) The 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise. [MDCX](https://aibio.space/companies/medicus-pharma/)
272. Debt Financing · 2025-09-10 [Celcuity upsizes term loan facility to $500 million with Innovatus and Oxford Finance](https://aibio.space/news/celcuity-upsizes-term-loan-facility-500-million-innovatus-oxford/) Celcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones. [CELC](https://aibio.space/companies/celcuity/)
273. Debt Financing · 2025-09-03 [Precigen draws $100.0 million at closing of Pharmakon senior secured term loan facility](https://aibio.space/news/precigen-draws-100-0-million-closing-pharmakon-senior-secured-term/) Precigen entered a five-year senior secured loan agreement with funds managed by Pharmakon Advisors. A $25.0 million delayed draw tranche is available until June 29, 2027, and the loans mature September 3, 2030. [PGEN](https://aibio.space/companies/precigen/)
274. Debt Financing · 2025-08-21 [Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031](https://aibio.space/news/novavax-agrees-issue-225-0-million-4-625-percent-convertible-senior/) About $49.7 million of the new convertible notes would be sold for cash, and about $175.3 million would be exchanged for 2027 notes. The exchange gives Novavax no cash. The company expects to close on or about August 27, 2025. [NVAX](https://aibio.space/companies/novavax/)
275. Debt Financing · 2025-08-12 [Armata Pharmaceuticals enters $15 million secured term loan with Innoviva at 14.0% interest](https://aibio.space/news/armata-pharmaceuticals-enters-15-million-secured-term-loan-innoviva-14/) A $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025. [ARMP](https://aibio.space/companies/armata-pharmaceuticals/)
276. Debt Financing · 2025-08-12 [CorMedix completes $150,000,000 convertible senior notes private placement due 2030](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/) CorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture. [CRMD](https://aibio.space/companies/cormedix/)
277. Debt Financing · 2025-08-12 [CorMedix completes $150,000,000 convertible senior notes offering due 2030](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/) The 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount. [CRMD](https://aibio.space/companies/cormedix/)
278. Debt Financing · 2025-08-06 [ADMA Biologics enters $300 million credit agreement led by J.P. Morgan, repays Ares facility](https://aibio.space/news/adma-biologics-enters-300-million-credit-agreement-led-j-p-morgan/) The agreement provides a $75 million term loan and a $225 million revolving credit facility, both maturing August 5, 2028. ADMA used the proceeds to pay off its earlier facility with Ares Capital Corporation. [ADMA](https://aibio.space/companies/adma-biologics/)
279. Debt Financing · 2025-08-06 [Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund](https://aibio.space/news/oncotelic-therapeutics-issues-560-000-secured-convertible-note-mast/) Oncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales. [OTLC](https://aibio.space/companies/oncotelic-therapeutics/)
280. Debt Financing · 2025-08-01 [Celcuity completes $201,250,000 offering of 2.750% convertible senior notes due 2031](https://aibio.space/news/celcuity-completes-201-250-000-offering-2-750-percent-convertible/) Celcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering. [CELC](https://aibio.space/companies/celcuity/)
281. Debt Financing · 2025-07-30 [Propanc Biopharma sells $112,350 convertible note for $107,000, with 22% annual interest](https://aibio.space/news/propanc-biopharma-sells-112-350-convertible-note-107-000-22-percent/) Propanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003. [PPCB](https://aibio.space/companies/propanc-biopharma/)
282. Debt Financing · 2025-07-18 [Abeona Therapeutics cuts term loan rate to 11.75% and issues Avenue warrants](https://aibio.space/news/abeona-therapeutics-cuts-term-loan-rate-11-75-percent-issues-avenue/) Abeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance. [ABEO](https://aibio.space/companies/abeona-therapeutics/)
283. Debt Financing · 2025-07-09 [Galectin Therapeutics gets new $10 million credit line from chairman Richard Uihlein](https://aibio.space/news/galectin-therapeutics-gets-new-10-million-credit-line-chairman-richard/) The new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance. [GALT](https://aibio.space/companies/galectin-therapeutics/)
284. Debt Financing · 2025-07-07 [Pacira BioSciences enters $300.0 million revolving credit facility, repays term loan A](https://aibio.space/news/pacira-biosciences-enters-300-0-million-revolving-credit-facility/) The July 3, 2025 credit agreement is a $300.0 million senior secured revolver maturing July 3, 2030, and Pacira used part of it to repay its term loan A without prepayment penalties or fees. Wells Fargo Bank is administrative agent, and Wells Fargo Securities, Citizens Bank and Truist Securities are joint bookrunners and lead arrangers. [PCRX](https://aibio.space/companies/pacira-biosciences/)
285. Debt Financing · 2025-06-27 [Bausch + Lomb closes €675 million secured notes offering, refinances 2027 term loans](https://aibio.space/news/bausch-lomb-closes-675-million-secured-notes-offering-refinances-2027/) The notes mature January 15, 2031 and pay three-month EURIBOR plus 3.875%. The company also arranged a $2.325 billion term loan and an $800 million revolver, using the proceeds to repay and refinance existing debt. [BLCO](https://aibio.space/companies/bausch-lomb/)
286. Debt Financing · 2025-06-23 [Aytu BioPharma extends Eclipse term loan and revolver to 2029, adds $1.5 million advance](https://aibio.space/news/aytu-biopharma-extends-eclipse-term-loan-revolver-2029-adds-1-5/) Amendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%. [AYTU](https://aibio.space/companies/aytu-biopharma/)
287. Debt Financing · 2025-06-11 [Cogent Biosciences draws $50 million from term loan facility of up to $400 million with SLR](https://aibio.space/news/cogent-biosciences-draws-50-million-term-loan-facility-up-400-million/) Cogent drew $50 million of a term loan facility of up to $400 million from SLR credit funds on June 11, 2025. Most of the rest depends on pivotal trial results and a launch the company expects in 2026, and the debt falls due in 2030. [COGT](https://aibio.space/companies/cogent-biosciences/)
288. Debt Financing · 2025-06-09 [Integra LifeSciences amends credit agreement for covenant relief on leverage ratio](https://aibio.space/news/integra-lifesciences-amends-credit-agreement-covenant-relief-leverage/) Integra LifeSciences' June 6, 2025 amendment lifts its maximum consolidated total leverage ratio to 5.00 to 1.00 through June 30, 2026, then steps it down. The company says total indebtedness does not rise, but the amendment also restricts investments, new borrowing and transfers of intellectual property until the relief period ends. [IART](https://aibio.space/companies/integra-lifesciences/)
289. Debt Financing · 2025-06-04 [Elicio Therapeutics takes $10 million secured loan from investor GKCC](https://aibio.space/news/elicio-therapeutics-takes-10-million-secured-loan-investor-gkcc/) The note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026. [ELTX](https://aibio.space/companies/elicio-therapeutics/)
290. Debt Financing · 2025-05-19 [REGENXBIO receives $150 million at closing of royalty bond loan with HealthCare Royalty](https://aibio.space/news/regenxbio-receives-150-million-closing-royalty-bond-loan-healthcare/) A REGENXBIO subsidiary signed a limited recourse royalty bond with an affiliate of HealthCare Royalty Management, repaid only from royalties. The company says the $150 million received at closing extends its cash runway into early 2027. [RGNX](https://aibio.space/companies/regenxbio/)
291. Debt Financing · 2025-05-15 [Omeros exchanges $70.8 million of 2026 convertible notes for 9.50% notes due 2029](https://aibio.space/news/omeros-exchanges-70-8-million-2026-convertible-notes-9-50-percent/) The one-for-one exchange also means Omeros no longer has to make a $20.0 million term loan prepayment. Separately, it agreed to convert $10 million of the old notes into common stock. [OMER](https://aibio.space/companies/omeros/)
292. Debt Financing · 2025-05-13 [Altimmune draws $15.0 million under Hercules loan agreement for up to $100.0 million](https://aibio.space/news/altimmune-draws-15-0-million-under-hercules-loan-agreement-up-100-0/) The term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025. [ALT](https://aibio.space/companies/altimmune/)
293. Debt Financing · 2025-05-05 [Evolus signs amended loan agreement with $150,000,000 first tranche to refinance debt](https://aibio.space/news/evolus-signs-amended-loan-agreement-150-000-000-first-tranche/) Evolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid. [EOLS](https://aibio.space/companies/evolus/)
294. Debt Financing · 2025-05-02 [PDS Biotechnology sells convertible debentures for $20,000,000 to retire Horizon loan](https://aibio.space/news/pds-biotechnology-sells-convertible-debentures-20-000-000-retire/) PDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel. [PDSB](https://aibio.space/companies/pds-biotechnology/)
295. Debt Financing · 2025-04-21 [Invivyd signs term loan facility of up to $30 million with Silicon Valley Bank](https://aibio.space/news/invivyd-signs-term-loan-facility-up-30-million-silicon-valley-bank/) Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, can lend Invivyd up to $30 million in three tranches. Only the first $10 million is open without revenue milestones, and the loans are due March 1, 2029. [IVVD](https://aibio.space/companies/invivyd/)
296. Debt Financing · 2025-04-21 [Mind Medicine (MindMed) Inc. (now Definium Therapeutics, Inc.) refinances with $42.0 million loan](https://aibio.space/news/mind-medicine-mindmed-inc-now-definium-therapeutics-inc-refinances-42/) The company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded. [DFTX](https://aibio.space/companies/definium-therapeutics/)
297. Debt Financing · 2025-04-21 [Mind Medicine (now Definium Therapeutics) amends K2 loan to up to $120.0 million](https://aibio.space/news/mind-medicine-now-definium-therapeutics-amends-k2-loan-up-120-0/) The amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss. [DFTX](https://aibio.space/companies/definium-therapeutics/)
298. Debt Financing · 2025-04-07 [Neogen refinances term loan and revolver with $450 million term loan, $250 million credit facility](https://aibio.space/news/neogen-refinances-term-loan-revolver-450-million-term-loan-250-million/) Neogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms. [NEOG](https://aibio.space/companies/neogen/)
299. Debt Financing · 2025-04-03 [MoonLake draws $75.0 million of Hercules Capital loan facility of up to $500.0 million](https://aibio.space/news/moonlake-draws-75-0-million-hercules-capital-loan-facility-up-500-0/) MoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030. [MLTX](https://aibio.space/companies/moonlake-immunotherapeutics/)
300. Debt Financing · 2025-03-26 [Savara draws $30 million under Hercules Capital loan agreement, repays Silicon Valley Bank debt](https://aibio.space/news/savara-draws-30-million-under-hercules-capital-loan-agreement-repays/) Savara drew the first $30 million of a loan of up to $200 million from a group led by Hercules Capital, and used it to repay its Silicon Valley Bank term loan. Later draws depend on FDA approval of MOLBREEVI, a revenue milestone or lender approval. [SVRA](https://aibio.space/companies/savara/)
301. Debt Financing · 2025-03-12 [Armata Pharmaceuticals signs $10 million loan from largest holder Innoviva at 14.0%](https://aibio.space/news/armata-pharmaceuticals-signs-10-million-loan-largest-holder-innoviva/) The secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date. [ARMP](https://aibio.space/companies/armata-pharmaceuticals/)[INVA](https://aibio.space/companies/innoviva/)
302. Debt Financing · 2025-03-05 [CalciMedica signs loan agreement for up to $32.5 million, funds $10 million at close](https://aibio.space/news/calcimedica-signs-loan-agreement-up-32-5-million-funds-10-million/) The Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026. [CALC](https://aibio.space/companies/calcimedica/)
303. Debt Financing · 2025-02-20 [Heron Therapeutics extends Hercules loan maturity to as late as September 1, 2027](https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/) The later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier. [HRTX](https://aibio.space/companies/heron-therapeutics/)
304. Debt Financing · 2025-02-07 [Akebia Therapeutics draws $10.0 million Tranche C loan from Kreos, receives $9.3 million net](https://aibio.space/news/akebia-therapeutics-draws-10-0-million-tranche-c-loan-kreos-receives-9/) Akebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share. [AKBA](https://aibio.space/companies/akebia-therapeutics/)
305. Debt Financing · 2025-02-07 [Akebia extends Kreos loan tranche, draws $10.0 million and issues 1,153,846-share warrant](https://aibio.space/news/akebia-extends-kreos-loan-tranche-draws-10-0-million-issues-1-153-846/) Akebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years. [AKBA](https://aibio.space/companies/akebia-therapeutics/)
306. Debt Financing · 2025-01-22 [Provectus Biopharmaceuticals approves plan to seek up to $10,000,000 in convertible notes](https://aibio.space/news/provectus-biopharmaceuticals-approves-plan-seek-up-10-000-000/) The unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes. [PVCT](https://aibio.space/companies/provectus-biopharmaceuticals/)
307. Debt Financing · 2025-01-16 [Alto Neuroscience amends K2 HealthVentures loan, $20.0 million funded and maturity now 2029](https://aibio.space/news/alto-neuroscience-amends-k2-healthventures-loan-20-0-million-funded/) Alto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees. [ANRO](https://aibio.space/companies/alto-neuroscience/)
308. Debt Financing · 2025-01-13 [Inhibrx Biosciences gets $100.0 million at close of Oxford Finance term loan facility](https://aibio.space/news/inhibrx-biosciences-gets-100-0-million-close-oxford-finance-term-loan/) The loan agreement allows up to $150.0 million, with the remaining $50.0 million at the lenders' sole discretion. The loan matures January 1, 2030 and comes with warrants for 140,741 shares at $14.21. Oxford Finance LLC is collateral agent. [INBX](https://aibio.space/companies/inhibrx-biosciences/)
309. Debt Financing · 2025-01-13 [Verastem sells $75.0 million of notes to Oberland Capital and repays Oxford loan](https://aibio.space/news/verastem-sells-75-0-million-notes-oberland-capital-repays-oxford-loan/) The note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary. [VSTM](https://aibio.space/companies/verastem/)
310. Debt Financing · 2025-01-13 [Inhibrx Biosciences closes Oxford Finance loan of up to $150 million, funds $100 million](https://aibio.space/news/inhibrx-biosciences-closes-oxford-finance-loan-up-150-million-funds/) The five-year facility pays interest only until March 2028. Oxford also received warrants for 140,741 shares at $14.21 per share. [INBX](https://aibio.space/companies/inhibrx-biosciences/)
311. Debt Financing · 2024-12-23 [Cingulate raises $5 million net through $5,480,000 unsecured promissory note](https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/) The note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025. [CING](https://aibio.space/companies/cingulate/)

---
Source page: https://aibio.space/debt-financing/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biotech convertible notes, term loans and debt financing", 2026-10-31, https://aibio.space/debt-financing/